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ABSTRACT
Aim: This thesis reports on the study on the implementation of a warfarin-management
strategy into residential aged care facilities (RACFs) providing high-level care. The research
question investigated in the study was “does the development and implementation of a
new warfarin-management strategy into RACFs enhance the outcome for high-level care
residents and is it usable and acceptable to those responsible for warfarin management?”
The evaluation of the acceptability, usability and safety implications of the strategy, which
involved the introduction of a warfarin-specific medication chart in concert with education
sessions, is also described.
Background: The study originated from the findings of previous research into the barriers to
quality use of warfarin in RACFs from the perspectives of General Practitioners (GPs) and
Registered Nurses (RNs) working in this setting which identified communication, monitoring,
documentation and decision-support inadequacies in the systems employed. There is highlevel evidence for the efficacy of the anticoagulant warfarin in reducing the risk of
thromboembolism; yet there is a paucity of evidence for its benefits in older, frail people
with comorbidities and complex medication regimes for whom the risks of haemorrhage are
higher than populations in the landmark studies. Hence the necessity for safe medication
practices around warfarin in this setting. The safety of warfarin is paramount in the context
of the changing environment of residential aged care and as a continuing option in the
expanding pharmacological options for anticoagulation.

The literature confirmed that quality use of all medications and particularly warfarin is
difficult to achieve in residential aged care. From the recommendations of the previous
research, a standardised warfarin-specific medication chart was inductively developed by all
vi

healthcare disciplines with roles in medication management, and it is introduction of this as
part of an overall management strategy and its evaluation, that was the focus of the study.
Methods: A mixed-methods approach was employed in the study, utilising a pre-test/posttest with intervention design. The multi-intervention design comprised of warfarineducation sessions for RACF staff, an explanation of the proposed warfarin-management
strategy to prescribing GPs, dispensing pharmacists and RACF staff, the development and
introduction of the warfarin-specific medication chart and ongoing participation in the
implementation of the strategy as required. Descriptive statistics were used to assess the
indicators of the quality use of warfarin and the safety implications of the warfarinmanagement strategy for high-level care residents receiving warfarin throughout the study,
as well as its acceptance and usability. Additionally, thematic analysis of interviews with
participant GPs and RNs responsible for warfarin management was used to evaluate the
strategy. Potential and actual warfarin-related adverse events were also recorded from the
participant residents’ medical histories and medication charts.
Findings: The study participants were 23 residents who received warfarin, nine GPs and the
nurses from three Illawarra RACFs. Fifty-six nursing staff with a role in medication
management participated in the warfarin education sessions delivered with the
implementation of the strategy implementation. Data analysis demonstrated a trend
towards an improvement in surrogate measures of quality use of warfarin when the posttest phase results were compared to those from the pre-test. Thematic analysis of semistructured interviews with the GPs and RNs found that the strategy provided more accurate
and preferred documentation of essential information, formalisation of the roles in warfarin
management, reduced time and improved workflow compared to previously used methods:
all with the potential impact on improving the safety of warfarin. The other quality
vii

indicators analysed did not differ obviously throughout the study; however, instances were
noted of changed nursing practices in response to the education sessions.
Conclusion: The warfarin-management strategy introduced into Illawarra RACFs was
evaluated as being acceptable and easy to use as well as providing decision-support to
improve warfarin prescribing, monitoring and administration, and potentially reduce
warfarin-related adverse events and errors. In addition, this thesis describes the strategy
implementation in the context of the changing environment of residential aged care and the
expanding pharmacological options for anticoagulation and provides recommendations for
further approaches to augment the strategy and to enhance the quality use of all medicines.
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1 INTRODUCTION AND BACKGROUND
1.1 Introduction
As a person ages, so does the chance of acquiring an associated health condition. The
incidence of atrial fibrillation increases exponentially and the literature provides estimates
that over 10% of individuals older than 80 have this arrhythmia (Lake et al. 1989; Camm et
al. 2010). Atrial fibrillation is the most common cause of embolic stroke and is associated
with higher mortality and morbidity than strokes of other causes (Lin et al. 1996). The
anticoagulant warfarin has been shown to significantly reduce this risk (Aguilar, Hart &
Pearce 2007).

Warfarin is the most widely used oral anticoagulant in Australia (Campbell et al. 2001) and is
indicated for other thromboembolic disorders as well as atrial fibrillation, such as for the
treatment and prevention of venous thromboembolism including deep venous thrombosis
and pulmonary emboli, and thromboembolism associated with prosthetic heart valves
(AMH 2011). However there is an associated risk of haemorrhagic events (Levine et al.
2004). Conducting a pathology test of a warfarinised person’s blood is accepted clinical
practice to maximise therapeutic action and avoid bleeding complications (Campbell et al.
2001). This test based on blood clotting times is known as the International Normalised
Ratio or INR. The warfarin dose is adjusted to maintain the INR in a target range dependent
upon indication, with the change in dose directed by a healthcare professional, usually the
prescriber.
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The effect of warfarin is complicated by its complex pharmacokinetic and pharmacodynamic
parameters (Phillips & Ansell 2008). Other medications taken concurrently as well as many
patient factors influence its action. In testimony to its reputation of being a difficult
medication to manage (Wilson 2008; Beyan, Beyan & Acar Vaizoglu 2010; Lee & Crowther
2011), the literature is replete with case studies (Kanagarajah 2001; Makeham, Saltman &
Kidd 2008; Rose & Gilmore 2009), drug interaction studies (Ansell, Hirsch & Wenger 2002;
Ghiculescu & Pillans 2008; Wallerstedt et al. 2009), suggested dosing algorithms (Tait &
Sefcick 1998; Siguret et al. 2005; Queensland Government 2006) and endeavours to
enhance its safety (Lubliner et al. 2005; Dahri & Loewen 2007; Duff & Walker 2010); as well
as research into effective and safe alternatives (Eikelboom & Hankey 2004; Connolly et al.
2006; Connolly et al. 2009; Galanis et al. 2011). Hardly a professional pharmacy conference
passes without research presented involving warfarin (Saba 1999), or a description of an
organisation’s program to meet the challenges of this medication (Duff & Walker 2010). Yet
the advantages of warfarin are such that persistent efforts have also been directed to
increase the prescribing of this medication to those most likely to benefit from its
therapeutic efficacy (NPS 2009). Understanding the barriers to uptake and quality
prescribing of warfarin is a key to enhancing its efficacy and safety; issues raised with good
reason in Australian (Peterson et al. 2002; Bajorek et al. 2007) and international (Devereaux
et al. 2001; York, Agarwal & Exeowitz 2003) literature.

Warfarin continues to be prescribed for older persons whose permanent place of residence
is in institutions such as aged care facilities (Lau, Bungard & Tsuyuki 2004; Abel Latif, Peng &
Messinger-Rapport 2005; Warhaftig 2005; Papaioannou et al. 2010). Both high and low
levels of care are provided in such facilities, with those in higher care more totally
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dependent on staff to meet their medication needs (Australian Institute of Health and
Welfare 2010). Occupancy in high-level aged care places in Australian facilities have
increased, with the attendant complexities in medication regimens, and this has occurred in
tandem with the removal of specified staffing ratios from the regulations in most
jurisdictions (National Aged Care Alliance 2004), thus potentially compromising medication
safety (Thomson et al. 2009; Wilson et al. 2010). Communication issues between health care
professionals responsible for the medical management of residents, especially in regard to
medication regimens is not ideal, in either the Australian setting (Pierce & Fraser 2009) or
internationally (Rose & Gilmore 2009). Most Australian aged care facilities do not have
resident medical or pharmacy services and rely on visiting professionals; the availability of
general practitioners (GPs) to perform medication-related activities remains a concern, with
over half of facilities surveyed in a 2004 Australian sample indicating difficulties in obtaining
GP input (Gadzhanova & Reed 2007).

Precisely how many residents of aged care facilities receive warfarin is not known. The
prevalence of AF in American and Canadian nursing homes ranges from 7.5% to 17%, with
approximately half of these residents (3.8% to 8.5%) prescribed warfarin (McCormick et al.
2001; Lau, Bungard & Tsuyuki 2004; Abel Latif, Peng & Messinger-Rapport 2005; Field et al.
2011). Such data are not available for the Australian setting. Preliminary research within the
Illawarra region (Jordan & Mullan 2008) which was the genesis of the research described in
this thesis concluded that approximately 6% of high-care residents receive warfarin, based
on responses from participant GPs and managers of RACFs. From this a figure,
approximately 62 people (or 6% of 1041 available high-care beds available in the Illawarra)
can be assumed to be receiving warfarin in this setting.
3

Communication and observations from the managers and senior staff of local residential
aged care facilities (Illawarra Regional Medication Advisory Committee 2001 - 2006) have
voiced the following challenges to medication management, especially warfarin. Australian
legislation governing the charting of medications in aged care facilities appears lacking.
While GPs are required to review a resident’s medication regularly when they attend
facilities, most decisions about warfarin are made remotely without necessarily having all
vital information available. Medication practices in relation to warfarin have developed in
an ad-hoc manner and without a systemised or consistent approach. Clinical information
systems, including medication orders, are still predominantly paper-based. The situation has
been exacerbated with the changes in the skills-mix of the staff caring for high-level care
residents. Warfarin is pre-packaged by pharmacies in dosage administration aids which
makes dosage alteration difficult. National “Best Practice” guidelines have been developed
for medication administration in residential aged care facilities (APAC 2002) but do not refer
to warfarin management or its difficulties.

The long awaited alternatives to warfarin such as dabigatran are finally arriving. However
these have contraindications that are relevant to this patient population and also an
increased risk of bleeding for older people (Eikelboom et al. 2011; Legrand et al. 2011).
Despite the difficulties in managing warfarin now being old knowledge, reports of errors and
adverse effects continue (Makeham, Saltman & Kidd 2008; Wilson 2008). It is in on this
background that the current research was set. The following thesis outlines one previously
undescribed strategy to improve the management and potential safety of warfarin, while
raising some wider questions about quality use of medications in this population.
4

1.2 Background to research
In 2007, a National Prescribing Service (NPS) educational visiting program was delivered to
Australian GPs with the first “key message” to “Consider warfarin in all patients with atrial
fibrillation at moderate-to-high risk of thromboembolism” (National Prescribing Service
2009). An obstacle to this message voiced by GPs to the Illawarra NPS educator was the
difficulties in prescribing and managing warfarin in their patients in residential aged care.
Consequently, at the behest of the GPs, preliminary qualitative research was undertaken to
ascertain the barriers to quality use of warfarin in residential aged care facilities from the
perspectives of the GPs and those responsible for warfarin management- the registered
nurses (RNs) and managers of such facilities (Jordan & Mullan 2008). Logistical difficulties
associated with prescribing, monitoring and administration were consistently reported.
Also, communication of factors impacting on the safe use of warfarin was found lacking. As
a result of a multidisciplinary workshop to disseminate and discuss the results of the
research, a warfarin-specific medication chart was proposed that could function as a
prescription, monitoring and administration record. A pilot chart was inductively developed
which included features thought desirable by all disciplines: medicine, nursing and
pharmacy.

The following thesis describes the research undertaken to implement a warfarin
management strategy in residential aged care facilities providing high-level care. The multiintervention design comprised of warfarin-education sessions for RACF staff, an explanation
of the proposed warfarin-management strategy to prescribing GPs, dispensing pharmacists
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and RACF staff, the development and introduction of the warfarin-specific medication chart
and ongoing participation in the implementation of the strategy as required.

6

2 LITERATURE REVIEW
2.1 Introduction
This chapter will present a literature review which summarises the relevant research on
warfarin in older people and how the principles of the quality use of medicines, that is, safe,
appropriate, judicious and efficacious use (Australian Government 2000), apply. The aim is
to provide a background to the research, to verify its significance and to review and
evaluate relevant strategies that may be applicable to managing warfarin in the setting of
residential aged care. By documenting risk factors associated with adverse warfarin
outcomes, consideration can be given to approaches with evidence of enhancing the safety
of warfarin. As warfarin is handled within an overarching system of medication
management in residential aged care, the literature review will appraise relevant research in
this setting.

2.2 Search terms and descriptors
To define “aged” is difficult. In the context of “residential aged care”, the age of those living
in Australian residential aged care facilities has increased so that the proportion aged over
85 has increased as the proportion of younger age groups has decreased (Australian
Institute of Health and Welfare 2010). Even a specific textbook on medicines in aged care
acknowledges the quandaries in terminology and instead opts to classify those living in
residential aged care as “frail elderly” (AMH 2003). For the literature search, the terms
“Aged, 80 and over", “Aged” “geriatric” and “Aging” were used to capture the population of
interest.

7

Warfarin is an oral anticoagulant from the group of “coumarin derivatives”, which refers to
the chemical structure. As the mechanism of action is to antagonise the effect of vitamin K
in the formation of blood clotting factors, it is also known as a “vitamin K antagonist”
(Brunton, Chabner & Knollmann 2010). There are other medications in this group but
phenindione is the only one other than warfarin used in Australia and only rarely if there is
an intolerance to warfarin (AMH 2011). Hence, the specific search term “warfarin” was used
to avoid less inclusive hits.

An anticoagulant is prescribed to reduce the chance of thromboembolism. The efficacy of
warfarin is the focus of much literature and forms the evidence-base for many guidelines for
its use (Baglin, Keeling & Watson 2006; Ansell et al. 2008; Hirsh et al. 2008; Kearon et al.
2008; Camm et al. 2010; Wann et al. 2011). However the current research was to determine
if a new management strategy would, as one outcome, improve the safety or reduce the
risks of the adverse effects of warfarin (haemorrhage). Accepted measures of outcomes
related to safety of warfarin are the surrogate clotting parameters (the INR as described in
more detail below in 2.8.1.1) as well as factors that impact upon the pharmacology of
warfarin and hence the risk of adverse events. For these reasons, the literature review
included those factors that impact on the pharmacology of warfarin, the INR and its
requirement for regular monitoring and the clinical outcome of haemorrhage. Risk factors
contributing to adverse effects of warfarin and also measures of warfarin safety were
included in the search. The terms “adverse drug reaction”, “drug toxicity”, “haemorrhage”
and “risk factors” were employed. Efficacy was not a focus except for in the target
population of older people.
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An Australian layperson’s term for the institutions where frail, older people live and are
cared for is “nursing homes”, though since the repeal of the New South Wales (NSW)
Nursing Homes Act in 2004 the term “residential aged care facilities” is now applied particularly in the healthcare field. The terminology used internationally for these are
“homes for the aged”, “Long-Term Care”, “Housing for the Elderly” “Homes for the Aged”
and “Health services for the aged”. All of these terms were used in the search.

As the focus of the research was the management of a medication by healthcare providers
and not by the person for whom it is prescribed, literature on specific medication
management systems, errors and medication charts in the health care setting was also
sought.

2.3 Search strategy
2.3.1 Search strategy 1
The search terms were linked using Boolean logic and the comprehensive strategy is
reproduced in Appendix 1. This was executed in international MEDLINE and CINAHL medical
databases. A less exhaustive search strategy - so as not to overlook relevant articles - was
executed in smaller databases: PROQUEST Central, Informa Healthcare, SAGE Journals
online, SCOPUS, Mary Ann Liebert, Wiley Online Library and Science Direct. For literature in
the Australasian context, INFORMIT Health Collection was used. As the focus of much of the
early literature was the therapeutic effects of anticoagulants and their indications, this
current search was limited to that published since 2000.
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In addition to searching medical databases, grey literature was sought in the databases of
organisations relevant to quality use of medicines, medication management in residential
aged care and to aged care generally.

After duplicates were excluded there were 746 articles retrieved from the larger databases.
Fewer hits would have been obtained if more limits or the Boolean NOT operator had been
applied to the search. There was a danger in this of excluding potentially useful literature so
instead extensive exclusion criteria were applied to the results. These are detailed below.

The titles and abstracts of the hits were perused for relevance according to the inclusion
and exclusion criteria and there was snowballing of the references cited if these were
deemed applicable. Full-texts of articles were requested if not available via the electronic
databases. Few additional articles were obtained from the smaller databases although those
that were tended to be relevant to the Australian context.

2.3.2 Search strategy 2
The subject of most of the literature retrieved from the search strategy detailed above was
of warfarin for atrial fibrillation (although this was not a specific search term employed).
Therefore, an additional search was undertaken specifically on its use in for prevention of
clotting for other indications in the older person. Similar search terms as above were used
with the additional terms “heart valve prosthesis”, “venous thrombosis” and “pulmonary
embolism”. This additional search (strategy 2, also detailed in Appendix 1) was performed in
the major databases with 183 hits. Grey literature was also searched.
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2.4 Inclusion and exclusion criteria
The following inclusion criteria were applied to the search results to scrutinise for relevance:
•

participants: those who were prescribed or were potential candidates for oral
anticoagulation, especially if these included a consideration to the age of the
participant

•

setting: studies were included if set in the community, especially in institutionalised
care

•

outcome measures:

warfarin-related adverse events (actual or potential) and

indicators of quality of anticoagulation
•

quality of studies:
•

Descriptions of rigorous research (systematic reviews and randomised
controlled trials) as well as those describing lower levels of evidence (Friss &
Sellers 2009; National Health and Medical Research Council 2009)

•

Levels 1 and 11 evidence were important for the recommendations for the
therapeutic use of warfarin and these also were preferred over lower levels of
evidence for studies of quality measures of anticoagulation.

•

Cohort and case-controlled studies provide an indication of the influence of
exposure and the associated risk of developing an outcome, often determined
retrospectively (Gordis 1996). Observational studies are suitable in instances
when deliberate exposure would not be ethical, for instance to a drug-drug
interaction involving warfarin (Friss & Sellers 2009). A goal of the literature
search was to explore factors that influence the responses to warfarin
especially in an older person and so cohort and case-controlled studies were
appropriate study designs and therefore included.
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Anticoagulation is a therapeutic area replete with guidelines. Those relevant to the
participant population were included and will be referred to in the literature review to
provide context to the studies described.

The following exclusion criteria were applied:
•

initiation of warfarin and dosing algorithms

•

strategies to improve safety in the hospital setting

•

management of anticoagulation during procedures such as surgery

•

anticoagulation as prophylaxis in orthopaedics

•

management of adverse effects, notably intracranial haemorrhage

•

strategies to improve communication from hospital to community

•

warfarin management strategies in the community setting or in independent living
arrangements

•

comparative studies of warfarin and other antithrombotics (unless relevant to the
themes uncovered)

•

strategies designed to increase the uptake of warfarin prescribing in atrial fibrillation

•

the pharmacogenetics of warfarin

•

warfarin resistance (physiological, not ethical)

•

toxicity of warfarin unrelated to its haematological properties

•

consequences of subtherapeutic anticoagulation

•

commentaries

•

research into the “point-of-care” testing of INR
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•

medication management systems so dissimilar to the Australian context as to be
irrelevant.

2.5 Terminology used in review
Because of the differences between Australian and international nomenclature, the term
“residential aged care facilities” or RACFs will apply directly to the Australian context where
this has been used. “Residential aged care” will be used when referring to the instances
when the older person is being cared for outside of their own home but not in hospital and
“aged care” will be used when discussing more general literature of the older person.

Warfarin is also an antithrombotic which means that it inhibits further clot (thrombus)
formation or expansion. The terms “anticoagulant” and “antithrombotic”, for the purposes
of this review, can be used interchangeably but “anticoagulant” will be most common.

Much of the literature was specific for warfarin. When this was the case “warfarin” will be
used. If the literature included other vitamin K antagonist anticoagulants then the
terminology “oral anticoagulants” will be used.

2.6 Results
The results of the literature search were examined and grouped into the following themes:
•

Theme 1:

Warfarin in the older person and the evidence for its efficacy

•

Theme 2:

Quality and assessment of anticoagulation
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•

Theme 3:

Recognition of risk factors for warfarin-related adverse events and the

impact of these factors on the older person
•

Theme 4:

Quality use of medications particularly warfarin in residential aged

care.
The literature was not exclusive to one theme in all cases and when relevant studies could
be categorised into more than one theme, this will be alluded to.

2.7 Theme one: warfarin in the older person and the evidence for efficacy
Although warfarin has been used for other indications, the predominant indications are for
the treatment and prophylaxis of venous thromboembolism (most commonly deep venous
thrombosis (DVT) and/or pulmonary embolism (PE)), for primary and secondary prophylaxis
against cardio-embolic stroke in the presence of atrial fibrillation (AF) and as prophylaxis in
the presence of prosthetic heart valves. The results of the literature search were grouped
for these major indications.

For the indication of venous thromboembolism (VTE), eight relevant pieces of literature
retrieved were pertinent for the literature review. Three of these were studies (two
randomised, controlled trials and the third a prospective cohort study), three were
consensus guidelines and two included reviews of the literature, one with a decision support
analysis. Two consensus guidelines were retrieved for the indication of prophylaxis in heart
valves. The majority of the literature contributing to the review was for the indication of AF
and included high level evidence: three meta-analyses, two randomised clinical trials, five
lower evidence cohort studies and three consensus guidelines.
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2.7.1 Venous thromboembolism treatment and prophylaxis
The debate in literature for this indication over this last decade was not whether to use
anticoagulation per se, but about the optimal duration of prophylaxis after an episode of
VTE – that is, a PE and/or DVT. The literature is concerned particularly if the episode is
unprovoked, that is, one that has occurred without known risk factors. So the outcomes of
interest were

not

the

efficacy

of

anticoagulation, rather

the

recurrence of

thromboembolism after a treatment course.

Three studies into the optimal duration of treatment after an event were found (Agnelli et
al. 2001; Campbell et al. 2007; Prandoni et al. 2007). None of the participant populations
were particularly relevant to older persons in residential aged care and the median and
mean ages ranged from 53 to 69. Prospective, randomised, single-blinded designs were
used for two of the studies: three months of anticoagulant therapy was compared to twelve
months by Agnelli et al (2001) and six months by Campbell et al (2007) and the participants
were followed up for up to one year and at least two years, respectively. In both studies the
participant population was clearly defined with exclusion criteria relevant to the proposed
research, as it resulted in the exclusion of patients deemed to have ongoing mobility
concerns, major illnesses and limited life expectancy. The participants in the study by Agnelli
et al (2001) all had unprovoked episodes of VTE, whereas this applied to just under half of
the participants in the Campbell et al. (2007) study. Details of diagnostic criteria were
provided as were the definitions for good or poor anticoagulation control and for major
haemorrhage - an additional outcome of interest. Neither study’s results supported therapy

15

beyond three months in lowering the chance of recurrence of thromboembolism. Also, the
incidence of major haemorrhage was statistically significantly higher for the extended
treatment time of one year in the study by Campbell et al. (2007).

The final study was of lower evidence: a prospective study of a cohort of briefly
anticoagulated patients followed up for up to 10 years after the primary event (Prandoni et
al. 2007). The exclusion criteria again limits the generalisability and participants were
included if they agreed to follow-up, introducing some selection bias. This study has the
most relevance to the proposed research as the results quantified the risk of recurrence of
thromboembolism after a primary, unprovoked event or a secondary event due to
temporary risk factors. The cumulative incidence of recurrence at one year was 11.0%
increasing to nearly 40% by ten years. Several predictors for recurrence were analysed and
age was associated as a positive predictor. Although participants were actively followed for
up to 10 years by telephone and survey, sudden deaths and incidents occurring away from
the study centre were limitations to the reliability of the outcome data collected.

Other literature on the question of duration after an unprovoked episode of VTE comprised
consensus guidelines (American Geriatrics Society 2002; The National Working Party on the
Management and Prevention of Venous Thromboembolism 2004; Kearon et al. 2008),
decision support analyses (Haspel et al. 2009) and a review of the research (Kearon 2010).
Not surprisingly, given the paucity and inconsistency of the research on this question, these
acknowledge the uncertainties around the duration of anticoagulation with ‘1 – 2 years’
advised as ‘sufficient’ in the Australian guidelines (The National Working Party on the
Management and Prevention of Venous Thromboembolism 2004 5.2), ‘indefinite’ by
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American collaborative care guidelines (Institute for Clinical Systems Improvement 2011 p.
30) and long-term for idiopathic pulmonary embolism in the elderly (Haspel et al. 2009)
based on data from 65 and 80 year-old outpatients. Additional advice that the ‘risk-benefit
ratio of continuing such treatment be reassessed in the individual at periodic intervals’ is
offered in the American guidelines (Kearon et al. 2008 p. 456S). Whereas, in the situation of
a lone event with obvious (suspected) and reversible cause, the recommended treatment
courses are more definitive and range from three to six months (The National Working Party
on the Management and Prevention of Venous Thromboembolism 2004; Kearon et al.
2008).

In their “decision-analysis”, Hasper et al. (2009) reviewed the literature-based estimates to
calculate the rates of recurrences of idiopathic thromboembolism and also haemorrhage to
provide a comparison of outcomes of short-term warfarin therapy compared to long-term.
Their findings were that long-term warfarin therapy increased absolute life expectancy by
0.16 to 0.56 years when compared to short-term therapy and was most beneficial in 65year-old patients with no history of falls and least valuable in 80-year-old patients with a
history of falls. None of the studies utilised appeared to have participants in residential aged
care. The proposed research will include older people with a history of a venous
thromboembolism. Even if an accurate history is obtained, there is little evidence as to the
risks and benefits of extended warfarin use in this population in the setting of residential
aged care. Perhaps the latter American guidelines then offer the most pertinent guide; that
is, that the ‘risk-benefit ratio of continuing such treatment be reassessed in the individual at
periodic intervals’ (Kearon et al. 2008 p. 456S).
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2.7.2 Prophylaxis in presence of prosthetic heart valves
No specific studies were found in the search for this indication, only single case reports and
opinion pieces. Management guidelines were again retrieved and these recommended
lifelong anticoagulation for this indication with target INRs based on the type and location of
the valve or a target of 3.0 if this is unknown (Baglin, Keeling & Watson 2006; Hirsh et al.
2008).

2.7.3 Stroke prophylaxis in Atrial Fibrillation
Level 1 evidence supports the efficacy of warfarin in AF to reduce both the risk of the initial
stoke - that is, for primary prevention - as well as subsequent stokes- that is, for secondary
prevention. This is apparent whether warfarin is compared to placebo or antiplatelet agents
such as aspirin or clopidogrel (Aguilar, Hart & Pearce 2007; Hart, Pearce & Aguilar 2007;
Andersen et al. 2008). The calculated relative risk reduction in stroke of 64% (95% CI, 4974%) compared to placebo (Hart, Pearce & Aguilar 2007) provides such convincing evidence
that anticoagulant therapy, particularly warfarin, is recommended in international
guidelines as first-line therapy in those with AF considered at high-risk of ischaemic stroke
(Camm et al. 2010; Cairns et al. 2011; Wann et al. 2011).

Evidence from trial cohorts in AF has provided knowledge of risk factors for stroke. Based on
such cohorts as Framingham (Lloyd-Jones et al. 2004), a risk score known as CHADS2 assigns
one of six possible points in a person with AF to age older than 75 (Gage, Waterman &
Shannon 2001). An updated version of this scoring system (CHA2DS-VASc) now assigns one
of a possible nine points for age greater than 65 years, or two points for age greater than
75. This new score has high predictive value for the occurrence of stroke (Lip et al. 2010).
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The evidence then is robust that warfarin can reduce the risk of stroke, and age is a known
predictor of stroke. Thus evidence for the use of warfarin in the older person is necessary.
Paradoxically, there appears a paucity of studies specifically of oral anticoagulation in the
oldest old; although what precisely constitutes this remains undefined. What follows now is
an analysis of the studies where older age was an inclusion criterion.

In their meta-analysis of trials in AF, Hart et al (2007) document the mean age at entry for
the warfarin versus placebo trials as just 69 years and for those with the antiplatelet
comparator, 70 years. In a later meta-analysis by Andersen et al. (2008) of 16 trials, two
newer studies were included in which the mean age of participants was over 80 (Mant et al.
2007; Rash et al. 2007). These were the first randomised trials to appear that specifically
recruited older patients with AF. They were also the only two randomised, controlled
prospective trials which included the primary endpoint of efficacy that were retrieved via
the current search when a limit was applied to older age.

The outcomes reported from these two trials, especially from that of Mant et al (2007), are
referred to constantly and without caveat as evidence for warfarin in older people (Jacobs
et al. 2009; NPS 2009; Camm et al. 2010; Lip et al. 2010) and its relative safety compared to
aspirin in this population (Lip et al. 2010; Pisters et al. 2010; Lip et al. 2011). This is
surprising given the following reasons.

BAFTA was the Birmingham Atrial Fibrillation Treatment of the Aged (Mant et al. 2007) and
WASPO, the Warfarin versus aspirin for stroke prevention in octogenarians study (Rash et al.
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2007). Age older than 75 (BAFTA) and 80 (WASPO) were conditions of entry. Both studies
were in community-dwelling patients, compared warfarin with aspirin and were
randomised, open-label prospective studies. Open label could be considered ethical in this
scenario so as to avoid unnecessary blood tests in the control group. Blinding of outcomes
occurred in BAFTA; details of any blinding in WASPO were not provided. Exclusion criteria
for both studies were exhaustive and included limited life expectancy and additionally, a
history of recent fall/s, impaired cognition or a previous stroke in WASPO. This meant that
only 20% of the possible 5000 participants were recruited to BAFTA. It is not possible to
know the recruitment rate in WASPO, as ‘accurate data regarding the percentage of
octogenarians screened that were ineligible to participate were … not available’ (Rash et al.
2007 p. 153): a situation inconsistent with quality reporting of a randomised trial (Moher,
Schulz & Altman 2001) and potentially introducing bias. Both studies were underpowered to
detect differences in predetermined endpoints; in BAFTA for sub-group analysis according
to age and in WASPO, to detect a difference between the two treatment arms.

The conclusion of WASPO, that ‘dose-adjusted warfarin was significantly better tolerated
with fewer adverse events than aspirin 300 mg in this elderly population’ (Rash et al. 2007 p.
151) need to be interpreted with caution due to the deficiencies in study design, the lack of
recruitment details and the final participant numbers of only half of that calculated as
required to detect a difference in treatment arms. This is then low quality reporting of a
clinical trial according to CONSORT guidelines (Friss & Sellers 2009). In addition, the
conclusion is also based on only one component of the combined primary outcome.
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The results of BAFTA were that adjusted-dose warfarin significantly reduced the first
occurrence of stroke. Although BAFTA was a community-based study designed to answer
some of the uncertainties around prescribing warfarin to older people, an additional
exclusion criterion was ‘if [their] primary care physician judged….that the patient either
should or should not be on warfarin’ (Mant et al. 2007 p. 494), which reflects a real-life
dilemma. Taking this into consideration as well as the extensive exclusion criteria which
excluded 80% of possible participants, those who were recruited eventually would be
similar to people for whom a GP would have few qualms about offering warfarin. Because of
the selection bias the results cannot be generalised to all older people, especially those
frailer and in residential aged care.

The two remaining studies of warfarin efficacy in older populations in AF were both
retrospective, observational, cohort designs which used linkage of datasets to determine
the incidence of stroke and haemorrhage in older community-dwelling populations (Johnson
et al. 2005; Jacobs et al. 2009): one in rural Victoria, Australia and the other from a single
geriatric outpatient clinic in New York. The patient populations described were more
representative of that of interest except for their place of residence; that is, older and frail
people with co-morbidities and, included in the case of the Jacobs et al study (2009),
cognitive impaired people and those at high-risk of falls. The results were that the stroke
risk was low at 2.6% and 2% per year respectively, with high rates of haemorrhage (greater
that 10% and 6%) and overall mortality (30% and 20%). Although the stroke rates were
lauded as good outcomes and lower than that of other studies, the reliance on and
limitations of secondary records and the high rate of major haemorrhage observed could
question this as evidence to support warfarin use in this population. Also, in the New York
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study, the cause of death (stroke or haemorrhage) was not able to be determined and the
mortality was higher in those participants with documentation of dementia and/or falls.

2.7.4 Summary: evidence for warfarin in older people
Recruitment of older people is low in the studies of warfarin in venous thromboembolism
and AF. The early AF trials were noted to have excluded 61-97% of potential candidates,
because of concerns about the risk of bleeding or compliance issues (Gallus 1999). Many of
these would have been older patients and this reflects a real-life conundrum. Of the studies
recruiting older people, these lack generalisability and the results were equivocal when
efficacy and safety is considered. For those older patients who continue with warfarin
therapy outside the conditions of these trials, for instance in residential aged care, evidence
for ongoing benefits over risks was not found.

2.8 Theme two: quality use of warfarin
Grouped into this theme is literature that is concerned with quality: the use of indicators of
quality use of warfarin, and the resulting outcome of adverse events, either potential or
actual. The robustness of evidence of the literature that contributed to this theme varied;
with two meta-analyses and two systematic reviews providing higher levels of evidence and
one post-hoc analysis of a randomised controlled trial, two cohort studies, a retrospective
analysis of secondary sources and two cases of grey literature included. Four consensus
guidelines were referenced.
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Indicators of quality use of warfarin have been proposed. Surrogate quality markers such as
achievement of therapeutic INR, time the INR spends in the therapeutic range (Ansell et al.
2001), variations in INR and extreme INR values (Lee & Crowther 2011; Witt 2011) have all
been recommended. Outcome measures include the clinical indicators of potential or actual
warfarin-related adverse events (Witt 2011). This section will therefore be divided into
surrogate and outcome measures of quality. (The concurrent use of potentially
inappropriate medications could also be considered a measure of quality: this will be
discussed in theme four).

2.8.1 Quality use of warfarin: surrogate measures

2.8.1.1 The INR
Surrogate outcomes include laboratory results or readings that are a substitute for definitive
clinical outcomes (van Walraven et al. 2009). The INR is a surrogate measure used to
quantify the possible effectiveness or toxicity of oral anticoagulation. To approximate the
effectiveness and toxicity, target ranges of the INR for which to aim have been adopted
internationally, based on clinical research using randomised trials, case-control and
observational studies (Ansell et al. 2001; Ansell et al. 2004; Baglin, Keeling & Watson 2006)
and confirmed by a nested case-control study (Singer et al. 2007). However the safety of
warfarin is not assured by obtaining an INR within the therapeutic range, as the following
literature suggests.

Two relevant meta-analyses have been performed to systematically quantify the effect of
INRs above target range (“overanticoagulation” or “supertherapeutic” INRs) on the risk of
haemorrhage (Oake et al. 2007; Oake et al. 2008). These are Level 1 evidence with the
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specific research question of interest. Both investigated the effect of INR on
thromboembolic events as well, however only the outcome of haemorrhage will be
analysed in this review. Studies included were those of oral anticoagulants for all indications
that provided an accepted definition for major haemorrhage and that the INR at the time of
an event was known or able to be deduced. Both excluded studies of concurrent antiplatelet
therapy as these can contribute to bleeding events. Two-thirds of included studies were
community-based.

Although the outcomes of the two meta-analyses were expressed differently, similar
conclusions for clinical practice can be made. Oake et al (2007) calculated that
approximately half of the haemorrhagic events occurred above the target INR range of 2.0
to 3.0. While this appears to confirm the recommendation to aim for this target INR to
enhance safety, it also can be concluded that over half of the haemorrhages occurred at
INRs within or below the target range. Oake et al (2008) demonstrated that while major
haemorrhage can occur at an INR in the target range, the chance increases greatly when
above target so that for INRs between 3.0 and 5.0, the relative risk (RR) of a major
haemorrhage occurring was 2.7 (95% CI, 1.8- 3.9) and if the INR was greater than 5.0, 21.8
(95% CI, 12.1- 39.4). What is unknown from the included studies is the influence of other
patient factors on these outcomes such as demographics, co-morbidities and concurrent
therapies. Certainly there was no suggestion that any of the participants were cared for in
residential aged care. The INR at the time of haemorrhage was extrapolated in some cases
so that is a further limitation. But what they do provide is some reassurance that dosing
warfarin to a target INR of between 2.0 and 3.0 can reduce the risk of haemorrhage, while
recognising that other factors must influence this outcome as well.
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2.8.1.2 The time spent in the therapeutic range (TTR)
An oft-quoted risk of bleeding is a “labile” or “fluctuating” INR (Campbell et al. 2001), but
how this is assessed is not always clear. One proposed measure of quality is the frequency
that the INR spends in the therapeutic range, referred to as the TTR. This can be determined
for an individual or for a cohort; for instance, patients of a clinic to assess the quality of its
practice or those recruited to a study. Various methods have been used to approximate the
TTR and definitions vary (Scmidtt, Speckman & Ansell 2003; Ansell et al. 2008; Phillips &
Ansell 2008; Lee & Crowther 2011; Witt 2011); for instance, in some cases it is proposed
that the INRs of warfarin-naïve patients or those for whom therapy is interrupted be
excluded from analysis as these are more likely to be quite labile (Ansell et al. 2008; Witt
2011).

A systematic review was conducted of studies in which a calculation of TTR was performed
to determine the range of TTRs achieved (van Walraven et al. 2006). The findings were that,
from the 67 studies included, INRs were therapeutic 64% of the time and that higher TTRs
were achieved through anticoagulation clinics. Unfortunately, any clinical outcomes that
occurred and if a correlation existed with the TTR were not provided, so this provides purely
an analysis of the quality of a surrogate measure. For a TTR to have credibility as an
indicator, evidence should be available to link it with clinical outcomes. The guidelines
published by the American College of Chest Physicians (Ansell et al. 2008) state that
correlations have been shown between TTR and clinical outcomes (thromboembolism and
bleeding) across a wide range of studies.
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Therapeutic outcomes were linked with TTRs in a large, multi-centre, randomised controlled
trial comparing oral anticoagulation to an antiplatelet combination in older people with AF.
Post-hoc analysis of the TTR and clinical outcomes was undertaken (Connolly et al. 2008)
and although the overall results of this study (known as ACTIVE-W) supported warfarin over
the antiplatelet combination treatment arm, the analysis showed that for those centres with
a low TTR, in these findings less that 65%, a significant difference in outcome between the
treatment arms was not found.

Clinical outcomes correlated with calculated TTRs as well in a lower quality, retrospective
cohort study based on linkage of three datasets (Morgan et al. 2009). Although there are
limitations of such a design and confounders could not be excluded, it is a community-based
study that demonstrated no significant improvement in stroke occurrence in any warfarintreated group compared to those not treated with warfarin unless the TTR was 71% or
above. The other outcome of interest in this study was mortality due to cerebrovascular
disease. There was no difference in the cerebrovascular mortality in the groups treated with
warfarin with TTRs below 40% compared to the groups not receiving warfarin. Due to the
retrospective use of datasets (in this case using ICD-9 and ICD-10 coding from routine
mortality data), the cerebrovascular codes were for all strokes without differentiation
between occlusive or haemorrhagic, meaning that it was not possible to determine if the
mortality was due to toxicity or ineffectiveness of warfarin. However, this study provides
support to the therapeutic benefits of achieving TTRs above 70% and the benefit in avoiding
TTRs below 40% to reduce cerebrovascular mortality.
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The safety of oral anticoagulation was the outcome of interest in a systematic review of
studies which had reported the surrogate measure of time in the therapeutic range (Wan et
al. 2008). In this review, a distinction was made by the researchers between the measure of
the TTR and the percentage of INR values in the therapeutic range: two indicators that are
often grouped together in other studies. The findings were that while the percentage of
time above range did not have a positive correlation with major haemorrhage, the TTR did,
so that an 8.3% increase in the TTR significantly reduced the event rate of major
haemorrhage. Hence this study provides some evidence for enhanced safety outcomes
being achieved with higher TTRs. The mixed results from all studies reviewed provide
support to the statements that, while the TTR may provide a measure of quality, the varying
definitions and inclusions make comparisons across studies difficult (Scmidtt, Speckman &
Ansell 2003; Ansell et al. 2008; Phillips & Ansell 2008)

2.8.1.3 Extreme INR values
A further process measure of quality of anticoagulation that could be applied in older
people, as proposed by Witt (2011) is the incidence of extreme INR values. This suggestion is
based on only one retrospective cohort study (van Walraven et al. 2007). Again, linkage of
datasets for community-treated patients was utilised. Data on major haemorrhage and
antecedent INR values enabled a calculation for the population-attributable risk that is, the
‘proportion by which the incident rate of the outcome in the entire population would be
reduced if the exposure [in this case extreme INRs] was eliminated’ (van Walraven et al.
2007 p. 1518). Extreme INR values were defined as those greater than 3.0, except for people
with prosthetic heart valves. The sensitivity analyses made this research appear
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complicated; however, the results are quite relevant to the assessment of quality of
anticoagulation for an individual. The authors concluded that one in four serious
haemorrhages occurring over a one-year period could be eradicated if an extreme INR was
avoided. Unfortunately, analysis for the oldest old was not provided as their definition of
“elderly” was people over 65 years of age; nonetheless it does provide evidence to minimise
the occurrence of INRs above 3.0.

2.8.1.4 Warfarin dose adjustment
Warfarin dose adjustment in response to an INR out of range has also been proposed as a
quality measure (Witt 2011). This is difficult to apply as there are no standards to cover all
scenarios. Australian consensus guidelines do provide guidance however if the INR is above
target (but less than 5.0) which is to ‘Lower the dose or omit the next dose of warfarin.
Resume therapy at a lower dose when the INR approaches the therapeutic range’ (Baker et
al. 2004 p. 494). Also, prescribing of warfarin has been the focus of quality improvement
programs in Australian hospitals (Duff & Walker 2010) and the indicator relevant to dosage
adjustment and the proposed research was 1.5: Percentage of patients with an INR above 4
whose dosage has been adjusted or reviewed prior to the next warfarin dose (NSW
Therapeutic Advisory Group 2007 p. 34). As previous studies referred to provide evidence
that INRs above 4.0 can increase the risks of haemorrhage, this appears a valid indicator and
relevant to the proposed research.
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2.8.2 Quality use of medicines: outcome measures

2.8.2.1 Potential warfarin-related adverse outcomes
Identification of potential warfarin-related adverse events as consequences of prescribing
and management has been the subject of quality projects in hospital and community
settings as well as residential age care. As the latter is the population of interest, studies
concentrating on this outcome contributed to the literature review. For this outcome, there
is an overlap with those included in Theme four: quality use of medications including
warfarin in residential aged care (section 2.10); hence they will be included in the discussion
of that theme.

2.8.2.2 Actual warfarin-related adverse outcomes
Other literature – all Australian - quantifies actual adverse outcomes attributed to warfarin
(Runciman et al. 2003; Clinical Excellence Commission 2006; Makeham, Saltman & Kidd
2008). Limitations of the datasets used mean it is not possible to discern the reasons for the
adverse events; that is, how much can be attributed solely to prescribing and monitoring of
warfarin and what may have been a result of patient misunderstanding or ignorance, which
arguably could also result from failures in the healthcare system (Makeham, Saltman & Kidd
2008; Phillips & Ansell 2008; Lowthian et al. 2009). Regardless of the details, warfarin
features highly as a medication associated with poor quality management. A rigorous review
of adverse drug events occurring across Australia was undertaken utilising several databases
including systematic literature reviews plus data from the Australian Bureau of Statistics,
Institute of Health and Welfare and the Council for Health Care Standards (Runciman et al.
2003). Warfarin featured prominently as the third medication or medication group most
commonly associated with a drug-related hospital admission. In addition, in the cited
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Quality in Australian Healthcare study within the research (Wilson et al. 1995), more than
5% of INRs were measured above 5.0 and the actual adverse incidence of abnormal bleeding
was 1%. This data provides indications as to the magnitude of the problem in Australia, even
though patient demographics and relevant characteristics were not known.

Hospital-specific medication incident reporting have reaffirmed the poor quality
management of warfarin in the Australian tertiary care setting when, after opioid analgesics,
warfarin was the second medication most likely to be reported as causing an unwanted
incident (Clinical Excellence Commission 2006) prompting a hospital safety alert (NSW
Health 2007). In the community setting, the “Threats to Australian Patient Safety” or “TAPS”
study collected anonymous reports from NSW GPs about adverse events that they had
recently managed (Makeham, Saltman & Kidd 2008). Approximately 18% of reports of all
medication errors involved warfarin which was the largest of all the medications reported.
The errors resulted in serious costly and clinical outcomes, with more than 20% of patients
involved requiring hospitalisation and resulted in the death of 7% of patients. This was a
community-based study and so it is feasible that some of the adverse occurrences involved
residents in aged care facilities, as it is the role of GPs in NSW to manage warfarin in this
setting.

2.8.3 Summary: quality use of warfarin
Evidence supports aiming for a target INR to reduce the incidence of adverse events from
warfarin. Other indicators of quality management of warfarin are maximising the time spent
in the therapeutic range, avoidance of extreme INRs and prompt review of a raised INR.
There is evidence that warfarin is a medication associated with adverse outcomes in the
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Australian context and it is conceivable that these can occur in older people in residential
aged care. Documentation of these outcomes can provide potential indications of the
quality of warfarin management.

2.9 Theme three: recognition of risk factors for warfarin-related adverse
events and how these impact in the older person
Text books and guidelines on warfarin provide precautions, warnings and contra-indications
to its use in certain situations and patient populations (Gallus 1999; Campbell et al. 2001;
Ansell et al. 2004; NPS 2009; AMH 2011). Yet unwanted bleeding episodes continue to
occur. Various characteristics of a patient receiving warfarin have the potential to influence
the outcomes and scores have been devised to help predict the risk of bleeding.
Unfortunately, the scores proposed to also assess the risk of stroke for an individual with AF
(for instance, CHADS2) share some of the same factors including previous stroke,
hypertension and age in HAS-BLED (Pisters et al. 2010) as well as HEMORR2HAGES (Gage et
al. 2006) and also diabetes (Shireman et al. 2006). It is the recognition – or lack of
recognition - of these characteristics and their interplay that is the third theme of the
literature review.

The evidence for factors potentially impacting on warfarin is gathered mainly from
observational studies as exposure to warfarin was not controlled. The studies contributing
to this theme included six prospective and three retrospective cohorts. One systematic
review was utilised as well as one set of relevant clinical practice guidelines.
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2.9.1 Age and bleeding risk
An INR above target in isolation may not result in an adverse haemorrhagic outcome,
although the chance of this occurring rises dramatically as the INR does (Oake et al. 2008)
and an INR above 3.5 is independently associated with an increased risk of intracranial
haemorrhage in an older population (Fang et al. 2004). As discussed in the first theme, while
the evidence for the efficacy of warfarin in the older person with AF is not overwhelming,
clinical practice guidelines consign age as an independent risk factor for bleeding based on
systematic reviews of the literature (Schulman et al. 2008). Not all researchers have drawn
the same conclusions regarding the influence of age on bleeding risk (Abdelhafiz &
Wheeldon 2008) and in an effort to reconcile these differences, reviewers have referred to
methodological differences in study design and patient characteristics as potential reasons
for the anomalies (Cheng 2006; Wyse 2007; Hylek & Magnani 2008). Small sample sizes,
study settings (anticoagulant clinics or general practice), length of anticoagulation therapy,
characteristics of patient population studied, gender balance, concomitant medications and
definitions of haemorrhage used all potentially impact on the overall conclusion as to
whether age is a determinant in bleeding risk.

2.9.2 Combination of risk factors for bleeding in the older person
Rather than concentrating the debate on whether age alone increases the risk of bleeding,
other studies researched the role of additional possible risk factors for bleeding with
warfarin in the older person. Again, similar to findings of previous studies, the results
sometimes differed. Some studies were retrospective and examined the presence of a risk
factor or factors of interest at the time of a major bleeding event (Fang et al. 2004;
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Wittkowsky et al. 2004); whereas others prospectively followed cohorts of patients treated
with warfarin over time or until a warfarin-related adverse event occurred and compared
outcomes to controls not exposed (Palareti et al. 2000; Poli et al. 2007; Abdelhafiz &
Wheeldon 2008; Abdelhafiz et al. 2009). The risk factors for bleeding in the older person
emerging from these studies were diabetes, raised or labile INRs, previous bleeding
episodes, concomitant antiplatelet medications, renal impairment and medication load (the
number of medications). While cognisant of the limitations of observational studies and
extrapolations and reliance on secondary sources of data, these still serve as valid cautions.

It is the interplay of various factors that appear to influence the outcomes for the individual
that can be surmised from the results of these studies and this interaction appears more
crucial in the older person. Indeed, the results of a prospective study by Poli et al (2007)
demonstrated that in the older person with the most risk factors for stroke, that is, a higher
CHADS2 score (and also greater recognised risk for bleeding), the number needed to treat
with warfarin to cause one major bleeding event (known as the number needed to harm, or
NNH) reduced with age so that for the oldest age group of 85 to 96 year-olds, was calculated
as ten. For the younger cohort aged between 75 and 79 with similar CHADS2 score, the NNH
was 126. It is perhaps not surprising yet paradoxical that some of the risk factors identified
as factors increasing the risk of bleeding are similar to exclusion criteria in the randomised
controlled trials of warfarin for AF.

The literature thus provides an indication of factors that increase bleeding risk, but
identifying these and acting before an adverse outcome occurs is the obvious preferred
course of action. Recognition of some of the factors and assessing the preventability of a
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warfarin-related event in an older person was the aim of a prospective cohort study of 114
patients requiring emergency admission for major bleeding (Beyan, Beyan & Acar Vaizoglu
2010). It was determined that known interacting medications such as antiplatelet agents
and antibiotics was used concurrently with warfarin in 83% of cases. This research was with
those treated in the community; however, in an Australian study in older inpatients, even
the hospital setting was not able to prevent the adverse outcome of raised INRs in 14 of 26
cases possibly in response to the addition of a medication known to interact with warfarin
(Su et al. 2008).

Many of the risk factors identified for bleeding in the older person are variables which when
combined could indicate a measure of frailty, as discussed in a systematic review of frailty
indices (de Vries et al. 2011). Certainly, from this review, a major frailty factor is nutritional
status and as half of the 350 study residents from eight Queensland RACFs were assessed as
either moderately or severely malnourished (Gaskill et al. 2008), frailty is a very real
occurrence. The impact of frailty on both the decision to use warfarin and the outcome if
used was investigated in a prospective, observational, cohort study (Perera et al. 2009).
Using a validated scale, those categorised as frail were significantly less likely to have
warfarin initiated on a diagnosis of AF in a major Sydney teaching hospital. On follow-up at
six months, those deemed as frail, according to the study classification, and receiving
warfarin or antithrombotic therapy had a higher risk of having had a major or severe
haemorrhage compared to non-frail, although the difference was not statistically significant
[hazard ratio (HR) = 1.35, P = 0.34]. The results of this inception cohort study would
underestimate the risk of major haemorrhage in a currently frail, older population in
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residential aged care who may well not have been considered frail when the decision to
commence warfarin was made.

2.9.3 Summary: risk factors for bleeding in the older person
There are many promulgated influences of bleeding in the older person on warfarin. Weak
levels of evidence exist to support the contribution of any particular influence. The
combination and interplay of risk factors is important, even moreso in an older and frail
population residing in aged care facilities. Although potential risk factors such as a high INR,
comorbidities, other medications, age and previous haemorrhagic events are generally
known, anticipatory recognition of these is essential to reduce the adverse outcomes of
warfarin. Studies have indicated that some warfarin-related adverse events in an older
person are predictable; although literature is lacking as to the success or otherwise of
strategies designed specifically to enhance safety by identification of these risks in a timely
manner.

2.10 Theme four: quality use of medications including warfarin in residential
aged care.
Grouped into this theme is the literature attempting to define indicators of quality use of
medicines, such as polypharmacy and studies of influences which threaten quality in the
setting of residential aged care. Research studies of activities relevant to warfarin are
specifically included. Due to the nature of the research, the literature provided low levels of
evidence and were retrospective, case-controlled or cross-sectional studies (seven),
prospective case-controlled or observational cohort studies (three), pre-test/ post-test with
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intervention (one), thematic analysis of key informant interviews (three) and grey literature
(two reports).

2.10.1 Medication load – including warfarin - in residential aged care
In 2009, three-quarters of the residents in Australian aged care facilities were appraised as
requiring high-level care (Australian Institute of Health and Welfare 2010); a scoring which
denotes the individual’s insufficient capabilities in behaviours, activities of daily living
and/or as having complex health needs. Residents tend to have a high burden of disease
and chronic conditions; a mean of nine medical conditions (range 3 to 24) was recorded in
one small Australian study of 48 residents (Khalil 2011). The daily medications prescribed to
residents of aged care is often high with Australian research indicating a range of 1 to 21
and an average between 9 and 10 daily (Somers et al. 2010; Khalil 2011). It is unknown what
the incidence of warfarin use is, however the following provides an estimate of its use.

Internationally the reported prevalence of AF in the population aged over 80 years is
approximately 10% and increasing (Go AS et al. 2001; Camm et al. 2010). A single study set
in a Western Australian town has provided an estimate of the incidence in Australians aged
over 80 as 11.6% (Lake et al. 1989). Using these and international statistics, it was estimated
that in 2010 over 240,000 people in Australia had AF (PricewaterhouseCoopers 2010). The
incidence of AF increases with age and in aged care facilities in Australia in 2009, the
majority of residents (28%) were in the 85 to 89 year old age bracket. There was almost an
equally high percentage (27%) aged 90 and over; a situation due to Australians living longer
and hence a change in the age distribution (Australian Institute of Health and Welfare
2010). The prevalence of AF in American and Canadian nursing homes ranges from 7.5% to
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17%, with approximately half of these residents receiving stroke prophylaxis with warfarin
(McCormick et al. 2001; Lau, Bungard & Tsuyuki 2004; Abel Latif, Peng & Messinger-Rapport
2005; Field et al. 2011). Such data does not appear to be available in the Australian setting,
although in the 2007 study into barriers to warfarin prescribing in Illawarra aged care
facilities (Jordan & Mullan 2008), approximately 6% of all residents received warfarin (range
across facilities, 3-20%). The GPs interviewed in that research estimated that this
approximated 40% of those with an indication for warfarin. Thus, warfarin is a potential
medication to be considered for an increasing proportion of residents in aged care.

2.10.2 Quality use of medications – the literature
Research into the quality of anticoagulation using any measure appears not to have been
published in an Australian context. Indicators of quality use of medicines generally in
nursing homes have been the subject of research, as described in this section. Such
indicators are medication errors, inappropriate prescribing, adverse drug reactions and their
preventability and other established quality indicators such as errors in medication
administration and management. The difficulty with defining inappropriate prescribing is
that much is consensus-based and can change with newer medications and evidence. Such
indicators are often based on Beers’ criteria (Beers 1997), or modifications of this.

The available literature on quality use of medications in residential aged care has been tabulated
Table-2-1. The level of evidence of the studies is low, as all are observational with the main
limitations that secondary data is used for collation of results.
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Polypharmacy has been defined by some as the use of five or more medications (le Couteur
et al. 2004; Shi, Mörike & Klotz 2008), nine or more mediations (Nguyen et al. 2006), or as
the prescribing and administration of more medications than are clinically indicated (Hughes
& Lapane 2011) - a definition that would require a supporting formal medication review.
Various indicators such as polypharmacy may be debated as to their contribution to poor
quality; however if outcomes are considered, “inappropriate” prescribing increases with
polypharmacy, and both are associated with adverse outcomes. For the studies in which
warfarin use was specified, polypharmacy rated highly as an indicator of poor quality use.

The literature in which indicators for the quality use of warfarin was specifically evaluated is
contained in Table 2-2.
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Table-2-1: Descriptive characteristics of studies of quality use of medicines in residential aged care
Quality indicator,
study location,
(authors, year)

Study design and sample

Instruments and tools

Outcomes of interest
(including any specific for
anticoagulants /antithrombotics)

Limitations of study

Inappropriate prescribing

Western Australia
(Somers et al. 2010)

Italy
(Ruggiero et al. 2010)

ADR
PID
QUM
CMT/A
LPN

Cross-section single chart
review of 351 RACF
residents;
dementia diagnosis;
mean age 85

PID defined using
modified Beer’s criteria
(1997);
Polypharmacy defined
as ≥ five medications;

mean number medications
9.75/day;
PID: 50% participants;
polypharmacy: 91% participants;
range of medications 1-21;

Volunteer of participants- possible
selection bias;
exclusion of medically unstable, endstage dementia or delirium

One year prospective
observational, multicentre;
1716 long-term residents
with long-term
medications from 31
nursing homes;
mean age 83

PID from updated
Beer’s criteria;
hospital admission
data- ICD-9;
rigorous assessment
tools for comorbidities
and geriatric and
cognitive assessments

cognitive impairment 42%;
median five medications/day;
PID: 48%, 12%, 6% participants with
one, two, three PIDs;

Causality could not be established
between PID and hospitalisation;
hospitalisation only one indicator of
severity of ADR or outcome of
concurrent PID;

adverse drug reaction
potentially inappropriate drug
quality use of medicines
certified medication technician/ aide
licensed practical nurse

RACFs
DDI
triggers

Participants with PID had
higher risk of hospitalisation during
following 12 months HR=1.25; (95%
CI 1.01, 1.56)
Warfarin was most frequent
medication to have PID prescribed
(42% combinations)

Residential Aged Care Facilities
drug-drug interaction
lab results (e.g., high INR, Hb or haematocrit changes);
new medications and antidotes, e.g., vitamin K; new
symptoms; hospitalisations; bleeding

Beer’s criteria not inclusive, for instance
of over-or under-utilised medication, is
consensus-based not evidence- based;
influence of prn medications on
hospitalisation cannot be excluded
HR
RR
LTC
prn

hazard ratio
relative risk
long-term care
“when required”
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Table 2.1: Descriptive characteristics of studies of quality use of medicines in residential aged care (continued)

Quality indicator,
study location,
(author, year)

Study design and
sample

Instruments and tools

Outcomes of interest
(including any specific for anticoagulants
/antithrombotics)

Limitations of study

Inappropriate prescribing (continued)
Helsinki, Finland
(Hosia-Randell,
Muurinen &
Pitkala 2008)

Cross-sectional study
all LTC residents of
Helsinki nursing
homes;
1987 participants;
mean age 83.7;

Medication charts &
records
PID: using Beers criteria;
DDI class D, i.e., clinically
significant according to
Swedish & Finnish
database

mean eight medications/day;
PID: 40% participants;
DDI class D: 5% participants;

Mixed methodology:
prospective purposive
random sampling of
55 LTC homes using
observations and field
work;
256 residents
mean age 85 years;

Resident medication
chart review;
Direct observation of two
medication
administration rounds;

70% residents had at least one error
(prescribing, monitoring, administration or
dispensing);
1.9 error per resident (95% CI, 1.64-2.17);
Emerging themes of factors contributing to
errors:
little sense of being in a “team”; skills-mix
contributes to errors; poor quality of resident
history; lack of responsibility-taking for the
system; poor communication;
40% residents had monitoring errors recorded
(anticoagulation not specifically mentioned)

Five warfarin DDIs (0.25% residents)

Clinical outcomes of PID and DDI
not investigated;
indications for medications not
known; regular meds only
recorded so role of prn or short
courses in DDI or as PID unknown

Medication errors
United Kingdom
(Barber et al.
2009)

Taped interviews of
medical, pharmacy and
nursing personnel

Semi-structured
interviews with
thematic analysis
ADR
PID
QUM
CMT/A
LPN

adverse drug reaction
potentially inappropriate drug
quality use of medicines
certified medication technician/ aide
licensed practical nurse

RACFs
DDI
triggers

Residential Aged Care Facilities
drug-drug interaction
lab results (e.g., high INR, Hb or haematocrit changes);
new medications and antidotes, e.g., vitamin K; new
symptoms; hospitalisations; bleeding

Possible selection bias as consent
not obtained from all LTC homes
approached

HR
RR
LTC
prn

hazard ratio
relative risk
long-term care
“when required”
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Table 2.1: Descriptive characteristics of studies of quality use of medicines in residential aged care (continued)

Quality indicator,
study location,
(author, year)

Study design and
sample

Instruments and
tools

Outcomes of interest including any specific
for anticoagulants /antithrombotics

Limitations of study

Electronic database
reports by nursing
home personnel;
Errors categorised as
potential/actual,
“near-misses” and
preventable
Medication errors
defined as a dose
given that was
discrepant with the
medication order;
distractions and
interruptions defined

22 errors per 100 beds;
1.8 preventable errors per 100-resident
months;
84% errors reached resident (actual)
6% errors were warfarin; i.e., second highest
reported error medication

Nursing home staff responsible for
error reporting; secondary source of
data and limitations because of this;
not a systematic search for errors;
data from outliers (large volume of
error reports) excluded from all
analyses
Prn medications and more specialised
meds given by higher qualified RNs,
requiring referral to monitoring e.g.,
laboratory results.
Overall error rate not provided;
Acknowledged sample size may limit
statistical significance;
Presence of observer may influence
results

Medication errors (continued)
Descriptive analysis of

Carolina, USA
(Hansen RA et al.
2006)

Columbia,
Missouri
(Scott-Cawiezell et
al. 2007)

ADR
PID
QUM
CMT/A
LPN

over 10,000 reports
from 385 nursing
homes over nine
months

90 day observational
study;
convenience sample
five nursing homes ;
site observations of
3200 medication
administrations by 39
staff of mixed
credentials

adverse drug reaction
potentially inappropriate drug
quality use of medicines
certified medication technician/ aide
licensed practical nurse

RACFs
DDI
triggers

RNs had an error rate of 35%, gave least
amount of medications, gave more specialised
medications and had most interruptions;
CMT/As had error rate of 34%, gave the most
medications, had the least interruptions;
LPNs had an error rate of 40%, and had the
most distractions;
Error rate not statistically different between
skills;
Significant relationship between interruptions
and error

Residential Aged Care Facilities
drug-drug interaction
lab results (e.g., high INR, Hb or haematocrit changes);
new medications and antidotes, e.g., vitamin K; new
symptoms; hospitalisations; bleeding

HR
RR
LTC
prn

hazard ratio
relative risk
long-term care
“when required”
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Table 2.1: Descriptive characteristics of studies of quality use of medicines in residential aged care (continued)
Quality indicator,
study location,
(author, year)

Study design and
sample

Instruments and tools

Outcomes of interest including any specific for
anticoagulants /antithrombotics

Limitations of study

Polypharmacy defined
as ≥ nine regular
medications ;
ADRs identified
through reporting and
search for “triggers”;
validated tool for
assessment of ADR

Positive correlation between number of regular
meds and risk of ADR;
“Polypharmacy” group: RR of experiencing an ADR
was 2.33 (95% CI, 1.54-3.52, p<0.001)

Chart reviews and
search for “triggers”
for ADR;
rating scale for
severity, potential or
“near-misses” ADR;
preventability

550 ADRs, half preventable;
1.89 ADR per 100 resident-months;
More severe ADRs more likely to be preventable
(RR = 2.1,
95% CI: 1.8 to 2.5, P< 0.001).
Warfarin second most common medication with
preventable ADR;
Almost 80% of all potential ADRs were with
warfarin: mainly excessively high INR values (>4)
due to errors in anticoagulation management

Single study site may limit
generalisability;
retrospective: relied on
documentation;
information not available if ADR due
to prn or short-course medication;
mean age younger than that in
other studies- may underestimate
risk for “oldest old”
Sample was about 1/5 of all nursing
homes due to voluntary
participation;
use of triggers can miss events;
reliance on documentation;
no direct medial assessment

RACFs
DDI
triggers

Residential Aged Care Facilities
drug-drug interaction
lab results (e.g., high INR, Hb or haematocrit changes);
new medications and antidotes, e.g., vitamin K; new
symptoms; hospitalisations; bleeding

Adverse drug reactions

California
(Nguyen et al.
2006)

Massachusetts
(Gurwitz et al.
2000)

ADR
PID
QUM
CMT/A
LPN

Case-controlled
retrospective one
month chart review of
335 long-term care
residents > 65 years in
one facility;
demographic and riskfactor matched
controls; mean age 72
Cohort study: all LTC
residents in 18 nursing
homes;
12 months
retrospective
observational study;
mean age 85

adverse drug reaction
potentially inappropriate drug
quality use of medicines
certified medication technician/ aide
licensed practical nurse

HR
RR
LTC
prn

hazard ratio
relative risk
long-term care
“when required”
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Table 2.1: Descriptive characteristics of studies of quality use of medicines in residential aged care (continued)

Quality indicator,
Study design and
study location,
sample
(author, year)
Quality prescribing indicators and barriers

Sweden
(Bergman et al. 2007)

Missouri
(Vogelsmeier, ScottCawiezell & Zellmer
2007)

ADR
PID
QUM
CMT/A
LPN

Instruments and tools

Outcomes of interest including
any specific for anticoagulants
/antithrombotics

Limitations of study

Cross-section of medications
of 8000 nursing home
residents;
“younger elderly” (65-79
years) and “older elderly”
(80+ years)

Quality indicators
set by Swedish
National Board of
Health and Welfare

Average number of regular
medications=nine;
65% had 10 or more drugs;
75% residents had prescription that was
graded as poor quality; statistically more
common in young elderly that old elderly
50% residents prescribed “antithrombotic
agents”

Analysis did not consider
diagnosis or indications; that
is, only a list of medications

Key informant interviews and
focus groups;
thematic analysis;
convenience sample staff and
pharmacists from five nursing
homes;

Semi-structured
interviews and
focus groups to
investigate barriers
to QUM in nursing
homes

Barriers to QUM highlighted documentation,
dispensing, administering and monitoring;
Poor communication and competing
demands common theme to all

No input from prescribers

adverse drug reaction
potentially inappropriate drug
quality use of medicines
certified medication technician/ aide
licensed practical nurse

RACFs
DDI
triggers

Residential Aged Care Facilities
drug-drug interaction
lab results (e.g., high INR, Hb or haematocrit changes);
new medications and antidotes, e.g., vitamin K; new
symptoms; hospitalisations; bleeding

HR
RR
LTC
prn

hazard ratio
relative risk
long-term care
“when required”
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Table 2-2: Descriptive characteristics of studies of quality use of warfarin in residential aged care settings
Study location,
(author, year)

Connecticut
(Gurwitz et al.
2007)

United States
(Aspinall et al.
2010)

TTR
BRI factors
ADR

Study design and
sample

Instruments and tools

Outcomes of interest

Retrospective
observational cohort
study using case-finding
approach;
490 residents on
warfarin in 25 nursing
homes for 12 months;
mean age 83; 70%
female

Residents’ medication charts and
records;
triggers for warfarin-related ADR;
rating scale for severity and
preventability, actual and potential
ADRs (defined as INR >4.5 and due to
error in management);
antecedent medication error if
applicable;
TTR

6-month retrospective
cohort study;
160 residents receiving
warfarin in 5 US veteran
affairs nursing homes;
mean age 71; majority
male

Quality of warfarin management
assessed by:
cohort TTR;
% residents with individual TTR > 50%;
factors in bleeding risk index (BRI)
recorded;
interacting drugs; comorbidities;
adverse outcomes (bleeding or INR>4.5)

time spent in therapeutic range
history of stroke, GIT bleeding, recent myocardial infarction,
diabetes mellitus, low haematocrit, poor renal function
adverse drug reaction

DDI
“triggers”

720 ADRs: 253 potential;
29% actual ADRs were preventable;
rate of combined actual and potential
warfarin-related ADRs (973) was 25.5
per 100 resident-months on warfarin
therapy (95% CI, 23.9-27.1 per 100
resident-months);
Rate of serious, life-threatening, or fatal
ADRs was 2.5 per 100 resident months
(95% CI, 2.0-3.0 per 100 resident
months): of these, 1.4 per 100 residentmonths (95% CI, 1.1-1.8) deemed
preventable;
majority warfarin drug errors were in
monitoring and prescribing;
TTR was under 50%
TTR 55%;
TTR above 50% for 49% participants;
low bleeding rates;
positive association between TTR and
length of time on warfarin;
INR above 4.5: 24 occasions in 15
residents

Limitations of study
Retrospective reliance on
secondary sources of
information

Analysis of correlation
between bleeding risk factors
and actual events not shown;
mean age younger, male
dominance so a skewed
population: not generalisable
to other residential aged care
settings

drug-drug interaction
lab results (e.g., high INR, Hb or haematocrit changes); antidote,
e.g., vitamin K; new symptoms; hospitalisations; bleeding

LTC
NS

long-term care
not significant
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Table 2.2: Descriptive characteristics of studies of quality use of warfarin in residential aged care settings (continued)
Study location,
(author, year)

Ontario, Canada
(Verhovsek et
al. 2008)

Ontario,
Canada
(Papaioannou
et al. 2010)

Study design and sample
Retrospective, observational
cohort study;
all residents in five LTC
facilities on warfarin (9%
residents =107);
mean audit time 9 months;
mean age 84
Warfarin electronic decisionsupport system for
prescribing and monitoring
implemented in six LTC
homes; 128 residents;
Pre-test/ post-test design;
Focus group, survey with
closed and open-ended
questions;
Four prescribers, eight nurses
/pharmacists/ administration
staff

Instruments and tools
Medication charts;
consensus list of “highly
probable” and “probable”
interacting medications;
prevalence of DDIs;
TTRs;
TTR and DDI relationship

Number of INRs measured,
TTR of all residents and each
LTC;
Percentage of INRs above
range (supratherapeutic) and
below range
(subtherapeutic);
Major adverse events

Outcomes of interest

79% residents with ≥1 DDI;
82% cases of new DDI had INR
performed within 7 days;
TTR = 54%;
residents with DDI had statistically
significantly lower TTR than those
without DDI
Trend to increased TTR (NS);
Little change in percentage INRs
above target, no change in
percentage INR below target
range;

Limitations of study
Small sample size; assumption that
DDI only was cause of INR fluctuation;
i.e., other factors not considered;
not all DDIs will result in INR changes;
e.g., pharmacodynamic DDIs such as
aspirin

System developed and
implementation driven by physicians
and pharmacists involved in quality
care (noted as “early adopters”),
potential bias;

Decrease in average number of
INRs per 30 days per resident (with
TTR maintained or slightly
improved)

Pre-test TTR already higher than other
studies (65%), significant change
difficult to achieve;

Decreased work-load, improved
confidence in management
decisions, generally easy to use

Commercial pharmacy provider
developed and supported IT required;
limits expansion potential;

No major adverse events reported
TTR
BRI factors

ADR

time spent in therapeutic range
history of stroke, GIT bleeding, recent myocardial
infarction, diabetes mellitus, low haematocrit, poor renal
function
adverse drug reaction

DDI
“triggers”

drug-drug interaction
lab results (e.g., high INR, Hb or haematocrit changes); antidote,
e.g., vitamin K; new symptoms; hospitalisations; bleeding

LTC
NS

long-term care
not significant
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2.10.2.1 Quality use of medication- medication administration in residential aged care
Additional literature was retrieved concerning the administration of medications to older
people in residential aged care. The literature retrieved spans both the practicalities of
medication administration as well as the legislative framework in which it operates. Some of
the concerns are universal, such as the practicalities of the administration of medicines and
some are peculiar to the Australian national or even state setting as it relates to legislation.
This additional literature was comprised of studies employing mixed-methodologies with
lower levels of evidence. As described in the following paragraphs, nine studies employed
survey, questionnaires and focus groups for qualitative analysis; there were three
observational studies, one study utilising an action research design, one multi-intervention
study using pre-test/ post-test design and interview, a policy directive and two sets of
guidelines. Additionally, one literature review was retrieved on medication administration
(Hughes 2008) as well as an Australian published perspective, comprising much of the
Australian literature featured in Theme (four) of the literature review (Wilson et al. 2010).

The dilemmas associated with the role of having the responsibility of medication
administration for older people in aged care facilities was the focus of much of this aspect of
the literature (Wright 2002; Barnes et al. 2006; Hughes & Goldie 2009). As the nature of the
residents dictate, ensuring actual consumption of medications is often difficult. A survey of
540 RNs in the UK was undertaken to describe the difficulties experienced in their RACFs
(Wright 2002). RNs reported that 15% of their residents regularly spat out tablets and 9%
hid them and in responding to this, more than half of the RNs said that they disguised the
medications with food (which the author raises as presenting ethical dilemmas) and 30%
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omitted the dose completely. Unfortunately, the scope of the survey did not include the
action the RNs took if it was omitted; information that is imperative when considering
response to therapy in the case of medications such as warfarin.

In a similar Australian purposive survey, the experiences of 11 RNs working in RACFs were
analysed (Barnes et al. 2006). The need to crush medications presented the RNs with quality
and ethical dilemmas, as they were unsure how much was absorbed. Again the practice of
insisting residents take medications was questioned, as the authors suggested that nurses
may not be upholding some of the value statements in the Code of Ethics for Nurses in
Australia (Australian Nursing Council). As in the UK survey, the actions taken when
medications were not administered were unrecorded. The RNs spoke of “informal
communication” with GPs, but the decision-making they felt, was often left to them- this
being influenced by their knowledge and professional experience.

Altering the physical characteristics of medicines was a focus of a Norwegian observational
study (Kirkevold & Engedal 2010) in which the data on medication administration to
approximately 2000 residents in 65 nursing homes were collected. A quarter of residents
received medications mixed with food or beverages (with half of these being unaware of
this) while 10% of residents received a medication whose physical form had been
inappropriately altered as determined by the Norwegian pharmaceutical compendium:
most commonly crushed or opened. Inappropriate administration practices were not
associated with a resident having a diagnosis of dementia or low function of activities of
daily living, leading the researchers to conclude that the practices of crushing tablets or
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opening capsules was arbitrary and that nurses often “omit to judge and evaluate their own
routines” (Kirkevold & Engedal 2010 p. 84).

A different perspective was explored in a qualitative study employing semi-structured
interviews of both nurses and GPs and additionally, older residents in Irish nursing homes
(Hughes & Goldie 2009). The main theme identified from analysis of the GP and nurse
interviews was control: GPs of the prescribing process and nurses of medication
administration. There was a recognition by healthcare providers that this led to a loss of
autonomy for the residents and that they had a right to be involved in decisions about their
care. The residents interviewed accepted control without question and did not wish to be
involved in medication decisions, unless they thought it was giving rise to an adverse event.
The authors concluded that the healthcare providers recognised the rights of the residents
but justified overlooking these for the sake of control. This study provided viewpoints not
uncovered in other literature; however a major limitation was that the resident participants
were self-selected and were unaccustomed to the interview situations- which may have
limited their disclosures.

The literature then suggests administration practices may have developed by necessity due
to the inherent constraints in the residential aged care environment. Two studies with
observational components quantified the nursing time devoted to medication
administration in nursing homes (Thomson et al. 2009; Munyisia, Yu & Hailey 2011); the
latter as part of an overall study into nursing time spent in all activities. The time-motion
study conducted by Thomson et al in Northern American long-term care facilities calculated
the administration medication administration times according to the care-needs of the
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residents. Those with the heaviest physical needs had the longest time observed for the
medication administration process. It was estimated that up to approximately 40% of a
registered nurse’s 7-hour day shift could be spent on medication administration. The
processes of preparation and provision of the medication to the resident were responsible
for the majority of time spent; although interruptions contributed substantially to the
recorded time. These times however were an underestimate of the total time taken, as time
spent in clarification of medication orders and documentation, as well as the administration
of prn (or “when required”) medications was not documented.

The study by Munyisia, Hugh & Hailey (2011) determined the time spent by registered
nurses and endorsed enrolled nurses in the process of medication administration as well as
in other activities. As the setting for this study was in the Illawarra region, it is pertinent due
to the local context and also the changes in legislation that has allowed medication
administration by endorsed enrolled nurses in NSW (NSW Health 2005). Approximately 18%
of time for both levels of nurses was spent on medication administration to residents in
high-level care, although “multi-tasking” was also documented with medication
administration a common “multi-tasked” activity. Thus similar results are seen in the
Illawarra study as for the North American.

The changes in legislation to allow endorsed enrolled nurses (EENs) to administer
medications in NSW (NSW Health 2005) was the focus of two articles on action research,
both describing the same study (Bellchambers & McMillan 2006; Bellchambers & McMillan
2007). This study was to develop an implementation project to enable ENs to become safe
and effective medication practitioners. The outcomes of the research included a set of
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principles to guide the extended role of ENs, although concluded that the changing role led
to a lack of clarity for all members of the aged care medication team. The then NSW Nurses
and Midwifery Board subsequently developed professional standards for the delegation of
medication administration (Nurses and Midwives Board 2006; Anonymous 2007), The
Australian Nursing and Midwifery Council has an overarching statement guiding supervision,
however this does not highlight medication administration specifically (Australian Nursing
and Midwifery Council 2007). Besides the study into time spent administering medications
referred to above by Munyisia, Hugh & Hailey (2011), there appears to be no further
published research into administration of medications by staff other than RNs in the
Australian context. Only one study in Missouri, as outlined below in Table-2-1, referred to
the varying skills-mix of those who administer medications in residential aged care (ScottCawiezell et al. 2007).
The content of the final Australian article retrieved, although the title suggests otherwise,
describes the improvement in knowledge of adverse drug reactions occurring in “the
elderly” for RNs (divisions 1 and 2) working in several RACFs across Victoria, Australia, after
participation in an education program (Lim et al. 2010). Utilising a pre-test/ post-test design,
the results do not distinguish between the level of training of the nurses, but so show a
significant difference in knowledge for the post-test period, based on the use of factualbased questions. Feedback from the participants was that their knowledge was increased
and that they were more vigilant to the possibilities of adverse events, although thematic
analysis of the responses was not provided by the researchers.
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2.10.3 Summary: quality of medication use in aged care facilities
International and Australian studies indicate generally poor quality use of medicines,
including warfarin in residential aged care settings, according to the indicators of
polypharmacy and prescribing potentially inappropriate medications, medications errors
and adverse drug reactions.

2.11 Overall literature review summary and conclusion
There is a wealth of literature on warfarin, as indicated alone by the large number of articles
that were excluded from this review. High grade level of evidence exists for the efficacy of
warfarin for the major indications, but not for all its intended recipients, most notably,
older, frail people. Managing warfarin safely requires intensive efforts to avoid the inherent
risks of haemorrhage and quality indicators of warfarin exist to maximise its safety and
minimise adverse events. Medication management in facilities providing residential aged
care present challenges to quality use of medicines, especially warfarin, due to the
complicated nature of the residents, their comorbidities and medications, and the
apparently insufficient strategies available to meet these challenges.

2.12 Gaps in the literature
The most obvious gap in the literature is of research inclusive of the population of interest;
that is, older, frail people with many comorbidities residing in aged care facilities. The
majority of such literature is focussed on the risks to this population of medications,
especially warfarin, whereas there is a paucity of data on efficacy. Additionally, research of
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successful strategies to counter the difficulties inherent with medication use in this setting,
especially warfarin, is lacking.

2.13 Purpose of the research study as informed by the literature
The literature has provided an indication as to the difficulties in achieving quality use of
warfarin in the setting of residential aged care. A systems-approach that could enhance
quality at all levels of warfarin management is missing. The warfarin-management strategy,
which includes a warfarin-specific mediation chart, is designed to overcome some of the
issues specific to warfarin, such as the paucity of data available to the prescriber and the
person administering warfarin, at the time when significant decisions are being made. More
generally, the strategy is designed to enhance the communication that the literature has
highlighted as deficient in the medication management process in aged care. Indicators of
quality use of warfarin require documentation in order to gauge the success of the warfarinmanagement strategy, as well as to suggest themes for possible future research, so that
optimal quality use of warfarin in this setting can be achieved.
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3 RESEARCH DESIGN
3.1 Introduction and research question
This chapter will provide the details of the methodology behind the research, the phases of
the study and methods employed in each phase, as well as the methods of data collection,
analysis and evaluation. The research had its genesis in a real-life clinical problem, as
described in the first chapter. A need was identified through prior local research into the
barriers of quality use of warfarin in residential aged care facilities and the current study
undertaken to pilot one possible solution. The literature review in Chapter 2 exposed a
paucity of published literature on strategies employed to improve the management and
safety of warfarin in residential aged care. The research question investigated in the study
was “does the development and implementation of a new warfarin-management strategy
into RACFs enhance the outcome for high-level care residents and is it usable and
acceptable to those responsible for warfarin management?”

3.2 Methodology
A research question defines whether the aim of the research is to discover, explore, explain,
describe or compare. The research question for this study (as articulated above) comprises
of two parts: the first part seeks to explore a relationship between two sets of variables
(those collected before the management-strategy with those collected after) and the
second to explore practitioners’ beliefs and preferences. Outcomes analysed were

•

measures of warfarin safety and efficacy

•

acceptance of strategy by users

•

usability of strategy by users
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When a project has stages that have particular aims, different types of data may be
generated and the way the data are used will vary according to the phase (Brannen 2005).
Multi-method research is employed to address the variety of questions posed in a research
investigation. The use of mixed methods research is recommended to facilitate looking at a
research question from a number of different angles, and the term can describe research
which utilises both qualitative and quantitative data collection and analysis techniques in
parallel or sequential phases (Andrew & Halcomb 2006-2007).
As the first part of the question seeks to compare variables, these will need to be defined
and methods of collection and analysis outlined. The variables need to be able to be
measured to allow for quantitative analysis (O'Leary 2004a). The variables that were
collected in the study for comparison are detailed in following section 3.10.1.2.
The purpose of the second part of the question is to engage in the process of collaborative
change and, as O’Leary (2004a) proposes, the research is more explorative, does not involve
variables but gathering data that can be analysed by qualitative methods. Questions that
investigate practitioners’ or patients‘ attitudes, beliefs and preferences and that cannot be
answered by experimental methods are best investigated by qualitative methods (Green &
Britten 1998). Thus the necessary data collection tools will allow for open-ended responses
and analysis of words.
A semi-structured, self-administered questionnaire was used as to collect data from the
practitioner participants to address the second part of the research question, as detailed in
section 3.10.3.1. The first part of this questionnaire used closed-ended questions in which
the choices are anticipated and nominal scale could be used for the answers (Dawson &
Trapp 2004). The second part of the questionnaire allowed respondents to put answers into
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their own words. This type of questioning is useful when the response is unknown and when
they will be analysed for themes and the results reported as individual or group response,
especially if the topic has not been studied before (Dawson & Trapp 2004). Thus, the selfadministered, semi-structured questionnaire allowed for quantitative analysis but also
provided the opportunity for the respondents to write answers to elaborate or if none of
the chosen responses fit (Dawson & Trapp 2004).
The method of sampling used for this exploratory study was non-random, purposive,
although was done with the goal of representativeness in mind (O'Leary 2004b). The
purposive sampling was used to ensure that the aims of the research could be met (O'Leary
2004b); however it is acknowledged that this type of sampling may introduce bias into the
results.

3.3 Setting
The research was conducted in the community setting, in Illawarra residential aged care
facilities (RACFs) and the surgeries of the GPs who had patients as residents prescribed
warfarin.

3.4 Population and sampling
The participants in the research were the nursing staff of the RACFs, older people who were
high-level care residents of these RACFS and prescribed warfarin at any time during the
study period, and their GPs. The research used non-random and purposive sampling of
RACFs, as all of those in the Illawarra known to provide high-level care for residents
potentially receiving warfarin were invited to participate. The self-selected RACFs who
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consented to participate in the study were considered typical of those within the Illawarra
geographical area, as each one was under the auspices of different umbrella organisations
with very different medication management structures. Residents were included if they
received warfarin and high-level care in the participant RACFs and their GP consented to
participate in the study. The residents themselves were not active participants; the
participation after consent was obtained (as reported in Ethical considerations, section 3.8
below) was that warfarin-relevant data were collected from their notes. The GPs were
included if they were identified by the RACF management as treating a resident receiving
warfarin and if they provided consent. Details of recruitment and consent are presented in
this chapter in phase 1, 3.10.1.1. The nursing staff participants were those who participated
in the warfarin education sessions conducted in the RACFs in phase 2 (described in section
3.10.2.1) and those who provided data for evaluation in phase 3 (described in section
3.10.3.1)

3.5 Sample size calculations
Quantitative data
For the quantitative outcomes related to measures of clinical outcomes for residents in
high-level care receiving warfarin, a sample size can be calculated As alluded to in the earlier
chapters on the background to the research and the literature review, approximately 6% of
older, high-care residents of Illawarra RACFs receive warfarin based on previous local
research (Jordan & Mullan, 2008). This is a valid percentage to use for a sample size
calculation for several reasons. This preliminary research was conducted wholly within the
Illawarra with 13 GPs and 13 RACF managers as participants; respondent GPs and managers
were common to both studies and the estimate is similar to that of international
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studies(McCormick et al. 2001; Lau, Bungard & Tsuyuki 2004; Abel Latif, Peng & MessingerRapport 2005; Field et al. 2011). The total sum of all high-level care beds available within the
Illawarra region is 1041- a figure obtained by adding all those of the individual RACFs. Thus
the population of interest can be calculated as 6% of 1041, or 62.From this total population
of 62, the sample size can be calculated. To detect a difference in the outcomes between
the pre-test population from phase 1 and the post-test population from phase 3, with
confidence level of 95% and confidence interval of 0.05%, a sample size of 53 residents was
calculated as necessary (National Statistical Service 2011), a method of estimation proposed
by O’Leary (O'Leary 2004b p. 105) A p-value of < 0.05 was considered to be statically
significant.

Qualitative data
The qualitative data collected for analysis were from all GPs and RNs who participated in the
study. The sampling of RACFs was purposive- all RACFs providing high-level care and had
residents receiving warfarin were approached with data collection occurring in three. Three
RACFs providing high-level care and with older residents receiving warfarin contributed to
the final data, a limitation further discussed in the limitations in 5.2.2. Although not all
RACFs were included in the study, all GPs and RNS who did participate provided data via the
semi-structured questionnaire. Thus the data was representative of the participating
population and further sampling for the purpose of theme saturation was not an aim.

3.6 Study design
This study used mixed methods and consisted of a pre-test/post-test with intervention
design (Friss & Sellers 2009) and evaluation. The mixed methods employed allowed for the
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collection of both qualitative and quantitative data. Quantitative data collected comprised
of retrospective and prospective warfarin-specific data, as appearing in the medical notes of
older RACF residents prescribed warfarin. These are described in more detail in section
3.10.1.2 Other quantitative data collected were from the close-ended questions of selfadministered semi-structured questionnaires, completed by participant GPs and RNs. The
technique employed for the collection of qualitative data was analysis of the open-ended
questions of the same questionnaires. These are described in more detail in section
3.10.3.1.
This study was undertaken in three phases. Phase 1 was the pre-test phase and comprised
of the recruitment of participants and retrospective collection of baseline data of residents
on warfarin in RACFs. Phase 2 was the intervention phase in which the implementation of
the warfarin management strategy occurred along with warfarin education provided to
nursing staff of participating RACFs. In phase 3, the post-test phase, resident data collection
continued.
The type of the evaluation was summative, or outcome evaluation; that is, the data
collected was used to evaluate the effectiveness of the strategy and to assess investigate
whether the study aims had been met (O'Leary 2004c). Warfarin-specific resident data were
collected during phases 1 and 3 to allow evaluation of the intervention, and data for
qualitative evaluation were collected from GPs and nurses at the completion of phase 3
using a semi-structured questionnaire. These three phases will be described in greater detail
in the following sections of this chapter and are depicted schematically in Figure 3-1.
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RACF = residential Aged are Facility

Figure 3-1 Overview of study methods in phases 1, 2 and 3

GP = General Practitioner
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3.7 The Intervention
A multi-intervention design was used. The warfarin management strategy comprised of:

•

A warfarin-specific medication chart was inductively developed by GPs, RNs with
experience in residential aged care and responsible for warfarin management, and
clinical pharmacists with experience in medication charts and analysis of medication
errors. This chart could function as a prescription, monitoring and administration
record.

•

A manual detailing the strategy and a poster with instruction were developed and
distributed to those responsible for warfarin management in RACFs.

•

Comprehensive warfarin education sessions for nurses working in residential aged
care were delivered, as described later in this chapter in section 3.10.2.1

•

Individual meetings with GPs prescribing warfarin to residents in RACFs and
dispensing pharmacists were undertaken to outline the strategy in detail

3.7.1 The development of the warfarin-specific medication chart
The prototype of a warfarin-specific medication chart (hereafter referred to as the “chart”)
was inductively developed with input from RNs and GPs working in aged care, and clinical
pharmacists familiar with prescribing, administration and monitoring requirements, and
sources of medication errors. The chart design was based on the results of a previous study
(Jordan & Mullan 2008) as described in the first chapter. The features and prompts of the
chart were included to overcome some of the barriers to quality use of warfarin identified in
this study; such as the paucity of information available to a GP when prescribing warfarin
off-site and away from the RACF, the target INR, previous warfarin doses and INR results,
and the actual dose being administered. During recruitment in phase 1 described below in
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section 3.10.1.1, the chart was modified based on consideration of suggestions by GP and
RN participants. The prototype warfarin chart that was introduced in phase 2 of the strategy
is reproduced in Appendix 2. Further modifications were made throughout phase 3 and are
discussed in Chapter 4: Findings.

3.8 Ethical considerations
Ethical approval to undertake this study was sought and obtained from the Human Research
Ethics Committee, University of Wollongong and the South Eastern and Illawarra Area
Health Service; approval number HE08/189 (Appendix 3). Due to a delay in commencing the
study, extensions were granted to the period of approval. The date of expiry of the
extensions was 6 August 2011. As the resident-data collection began in May 2010, threemonth retrospective data collected were obtained within the period of the Human Research
Ethics Committee approval (7 August 2009 to 6 August 2011).

Ethical considerations concerning the participants of this research (GPs, RACF managers and
staff, and residents) included maintaining anonymity, confidentiality and privacy, and
provision of optimum care for residents without intrusion or unnecessary interventions.
Collated de-identified data only were used and, when expressing qualitative results, the
respondents referred to only by their discipline and code. There was no audio or visual
recording of participants. Each RACF, GP and resident were assigned a numerical code that
was used on study documents to prevent identification and stored separately in a passwordprotected computer. All participants were informed that they could withdraw consent at
any time. In particular, nursing staff were reminded that attendance at the educations
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sessions and participation in the questionnaires during those sessions and the phase 3 semistructured interviews were voluntary and anonymous.

3.9 Data collection
The process of data collection in all phases was undertaken by the researcher. As descriptive
statistics are used to assess quantitative data these were used for analysis. Numerical data
was provided from the residents’ records relevant to warfarin. This was collected from a
variety of places, depending upon the RACF including sometimes wholly within the
individual residents’ medical notes (Bradma labels, care plans, doctors’ notes, hospital
discharge summaries, physiotherapists’ notes and pharmacy reviews) and medication
charts, or alternatively in specific sites for storage of INR results and pathology requests.
Warfarin information was also kept in folders where collective charts for medications
requiring extra monitoring or more labour-intensive input were held, along with charts on
insulin and opioids. All likely sources of warfarin-relevant information were used to gather
as much data as possible. The data were recorded utilising Microsoft Excel® spread-sheets.

The methods of data collection utilised in the pre-test phase (phase 1) and the post-test
phase (phase 3) were unchanged. The data sources used were the same; that is, any medical
or nursing record where warfarin-specific information was recorded.

Other quantitative data were obtained through closed-ended questions from semistructured interviews of GPs and nurses from RACFs; responses were also recorded on
Microsoft Excel® spread-sheets.
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To provide qualitative data, fieldnotes were recorded in the warfarin education sessions and
to the responses to open-ended questions in semi-structured interviews (O'Leary 2004) with
participant GPs and nurses. Responses to open-ended questions were either noted down by
the researcher from verbal answers provided, or written by the participants themselves.
Additional qualitative feedback offered by the participants was also noted. All responses
were subsequently transcribed and written as fieldnotes with the page numbers noted for
reference purposes.

3.10 Methods used in each phase and timelines
Recruitment of RACFs and GPs commenced in May 2010, resident data collection in June
2010 and final evaluations completed in December 2010.

3.10.1 Phase 1 (pre-test phase)
In the first phase of the study, recruitment of the RACFs, GPs and residents prescribed
warfarin occurred. Retrospective, baseline resident data were collected as described below
in section 3.10.1.2.

3.10.1.1 Recruitment and consent

3.10.1.1.1 RACFs and nursing staff
All Illawarra RACFs whose managers responded to the letter of invitation to participate and
provided consent participated in the study. (Written consent was not requested from
individual nursing staff members who participated in phases 2 and 3 of the study. Consent
was implicit with their participation in the education sessions and evaluations and
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participation in these was voluntary. All questionnaires completed in the education sessions
and responses to phase 3 semi-structured interviews were anonymous.)

3.10.1.1.2 GPs with patients as residents in RACFs
All GPs with patients who were residents receiving warfarin in participating RACFs were
invited to participate with a letter of invitation. After consent was obtained the researcher
met with the GPs in their surgery rooms and provided details of the study. A resource
manual outlining the warfarin management strategy was provided to all GPs, similar to that
left with RACFs. (The contents of the manual are described below in the outline of the
warfarin education sessions 3.10.2.1.4.)

3.10.1.1.3 Residents prescribed warfarin in RACFs
Once consent was provided by GPs, their patients who were receiving warfarin in the
participant RACFs were approached and invited to participate. These participants then were
older residents receiving high-level care in RACFs and prescribed warfarin. Their
participation was not active; their warfarin-relevant data were collected to assess the
outcomes of the warfarin-management strategy and to assist in its evaluation.

The invitation to participate was printed on a plain language, participant information sheet
printed in 14-point font and on yellow paper. Consent was requested for the researcher to
access their medical records. This process was facilitated by the RACF staff, so that the
researcher did not have direct involvement with the resident. Anonymity was thus
maintained in the event of a refusal. If a resident was thought not to have the cognitive
ability to grant informed consent, the resident’s nominated person responsible was
approached with information and a request for consent in the resident’s stead.
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3.10.1.2 Baseline retrospective resident data collection
Warfarin-relevant data from residents of RACFs prescribed warfarin (hereafter referred to
as “residents”) as listed below were collected in the pre-test phase (phase 1) to enable
comparisons with post-test data (phase 3) and outcome evaluations at the completion of
the study. The method of data collection is detailed in an earlier section of this chapter (3.9).
Up to three months of pre-test baseline data were collected retrospectively (depending on
availability). The following were recorded:
•

the possible indication for warfarin,

•

the target INR if noted,

•

INR results and date,

•

factors present known to impact on the warfarin,

•

communication of these to the prescriber (if documented),

•

comorbidities and intercurrent illnesses,

•

concurrent regular and prn medications,

•

“triggers” indicating possible adverse events that could be attributed to warfarin
(bleeding, use of vitamin K, hospitalisation).

The same data were collected at regular intervals throughout the post-test phase (phase3)
as noted in section 3.10.3.

In the pre-test phase (phase 1), if a possible warfarin indication was found anywhere in a
resident’s medical records this was taken as the likely indication. The warfarin-specific
medication chart contained a prompt to select the indication so when the researcher
recorded the indication in the post-test phase (phase 3), the only place that qualified for the
purpose of “documentation of warfarin indication” was on the chart.
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The documentation of the target INR during both phases was noted by the researcher. Prior
to implementation of the strategy in the pre-test phase (phase 1), it may have been
recorded anywhere in the residents’ medical notes. Whether this was documented was
noted and compared with documentation in phase 3. The warfarin-specific medication chart
contained a specific prompt for the target INR to be selected from those pre-printed on the
chart or written by the prescriber.

3.10.2 Phase 2 (Intervention with education)
Phase 2 was the intervention phase which included the warfarin education sessions
provided to staff of the RACFs and the implementation of the warfarin-management
strategy with the introduction of the new chart (Appendix 2) for all subsequent
prescriptions of warfarin.

3.10.2.1 Warfarin education sessions

3.10.2.1.1 Participants and outline of warfarin education sessions
Warfarin education sessions (hereafter referred to as the “sessions”) were undertaken in all
RACFs whose managers consented to participate in the study. The managers of the RACFs
encouraged all RNs to participate and facilitated their attendance as well as other staff.
Participants were all nursing staff with a role in the management of warfarin in any of the
RACFs designated as A,B,C or D and were comprised of managers, RNs, endorsed enrolled
nurses (EENs), carers with medication certificates and “team leaders” who could be from
any of the above skill-sets. Although warfarin administration was the role primarily of RNs in
some RACFs, other nursing and care staff were responsible for recording results, arranging
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INR tests, and faxing charts. It was therefore crucial for staff with these duties to be
cognisant of the strategy which involved all of these steps.

The sessions were developed and delivered by the researcher, a clinical pharmacist with
experience in education and repeated as necessary. They were iterative, so that themes
emerging from the participant responses during the early sessions were used to inform
subsequent sessions. As the outcomes of the study were dependent upon the engagement
and knowledge of the nursing staff participants, sessions for individuals were conducted at
any RACF if an RN had not had the opportunity to attend previously. The aim was for as
many RNs and staff with a role in warfarin management to attend as possible.

There was no formal recording of the exchanges in the interactive workshop (described
below); fieldnotes were taken of the discussions stimulated by the prompt questions and
the backgrounds of the participants which were offered without prompting. There was a
staggering of the rollout of these sessions which meant it was possible to tweak the format
and content of the workshops using matters that were of concern in those preceding, or
that were found during early days of data collection. A comprehensive overview of the
sessions and the learning objectives are found in Appendix 4 and they will be briefly
outlined here.

3.10.2.1.2 Warfarin questionnaires
To begin the sessions, only the RNs and EENs attending (hereafter referred to as “nurses”)
were asked to voluntarily and anonymously complete a short questionnaire about warfarin
management, described below. This was to gain insight into their baseline knowledge of
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factors that could influence warfarin as well as the present warfarin-related communication
practices with the visiting GPs. As per ethical considerations, no pressure was applied or
comment passed if a nurse attending the session chose not to complete the questionnaire.

The first set of eight questions of the questionnaire was knowledge-based. These questions
were chosen to gauge the level of understanding of how factors that may occur in a resident
for whom they care could potentially impact upon warfarin. Very brief vignettes were listed
and the participants asked about the potential impact (Table 3-1.) Based on nursing
pharmacology texts and warfarin literature (Chaffman 2001; Glasheen 2005; Tiziani 2008;
AMH 2011), all scenarios could potentially impact upon warfarin. Thus the response was
noted as accurate if the nurses answered “yes”. The vignettes were preceded with the
question “Do the following situations listed below have an impact on warfarin therapy for an
older resident in an Aged Care Facility (ie may affect International Normalised Ratio (INR) or
increase the risk of bleeding?)”.

For the second set of questions the same vignettes as in Table 3-1 were presented, however
the nurses were asked, “For an older person who is a resident of an Aged Care Facility and
receiving warfarin, in which of the following circumstances would you alert the resident’s
usual GP because of a potential effect on their warfarin therapy?”. Thus these questions
were not only knowledge-based but prompted the potential action of the nurse, were more
subjective and reflected actual clinical practice. All scenarios could potentially impact upon
warfarin so the “ideal” answer was defined as one that had the potential for the safest
outcome for the resident receiving warfarin; that is “yes”.
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Table 3-1: Vignettes for questionnaire for nurse participants: potential for impact on warfarin and the
subsequent course of action of the nurse

Proposed scenario
Resident has diarrhoea
Resident has been vomiting
Resident is not eating
Resident has other medication(s) started in the past week
Resident has not been taking warfarin
Resident has had other medication(s) ceased in the past week
Resident has a new infection
Resident has not been taking other usual medications in the past week

3.10.2.1.3 Interactive warfarin workshop
The sessions continued using an interactive workshop format, with warfarin-related prompt
questions openly posed to the participants (Appendix 5), supported by a PowerPoint®
presentation (Appendix 6). The researcher recorded responses and discussions arising from
the workshop as fieldnotes.

3.10.2.1.4 Session conclusion: explanation of the warfarin management strategy
The preceding workshop laid the groundwork to introduce the principles of the warfarinmanagement strategy. The study chart (Appendix 2) and a 21-page resource manual
developed by the researcher, were referred to at each session and a copy left with each
RACF. The early chapters contained in the manual detailed the strategy, with the
information provided under the following headings:
•

Introduction

•

The warfarin-specific management chart

•

Starting a new chart

•

The administration of warfarin
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•

GP Alert!: clinical changes in a resident which may impact upon warfarin

•

INR testing

•

Warfarin orders and pharmacy

The content of the remaining chapters were of the mechanism of warfarin, its actions,
interactions and monitoring requirements. Specific information was included on the
management of INR values above the target range in the relevant population (older people
who are at high-risk of bleeding) based on consensus guidelines (Baker et al. 2004). In
addition to these resources, a laminated A3 sized “how-to” wall poster (Appendix 7) was
provided for each RACF.

Reassurance as to the dynamic nature of the strategy and chart was provided and on-going
feedback was encouraged via use of an “issues register”. Open communication was
encouraged and the value of feedback emphasised.

3.10.2.2 Implementation of the warfarin management strategy
On completion of the warfarin education sessions, the warfarin management strategy
(hereafter referred to as “the strategy”) was rolled out in each RACF. Each successive INR
performed for each resident was a prompt to commence prescribing using the new chart.
The education sessions described above and the first use of the warfarin medication charts
were staggered in the roll-out in each RACF, with the researcher present on the occasion of
first use in each case. From phase 2 onwards, the researcher was available at least weekly in
the RACFs until the study completion to collect resident data and discuss the strategy.
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Pharmacists from the pharmacies that dispensed and packaged medications for the
participant RACFs were advised of the study in phase 2. The researcher met with each
pharmacist and provided the same resource manual as given to GPs and RACFs, described in
section 3.10.2.1, and a sample study chart (Appendix 2). This communication was necessary
as the chart was to function as a prescription from the GP to enable changed doses to be
packaged by the pharmacies, as was the practice in two of the participant RACFs. When the
doses of warfarin are packaged for administration, the pharmacists’ usual practice was to
generate a standard “sign-on” chart specifically for warfarin, although no dose or date
appeared on these. (Alternatively, the RNs of other RACFs would administer the warfarin
doses from an original container). Meeting with the pharmacists was undertaken also for
professional communication reasons, as a measure of good-will; although there was no
further participation by the pharmacists in the study.

3.10.3 Phase 3 (post-test phase)
Phase 3 was the post-test phase, which included
•

recruitment of residents newly admitted on warfarin using the same procedures
described previously in the pre-test phase (phase 1) (section 3.10.1.1),

•

ongoing resident data collection, as described in the pre-test phase (phase 1)
(section 3.10.1.2),

•

revisions made to the chart to enhance usability, based on feedback from users,

•

semi-structured interviews with GPs and RACF nurses, and

•

analysis of outcome data

The methods used for the latter two will now be expanded.
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3.10.3.1 Semi-structured interviews
At the completion of the post-test phase (phase 3), the GPs and RACF nurses who had been
actively involved in the strategy and using the charts were invited to participate in semistructured interviews in order to assess the usability and acceptance of the strategy.

3.10.3.1.1 GPs
The GPs were interviewed one-to-one in their surgeries, using the semi-structured interview
questions (Appendix 8). As well as providing answers to the questions, comments and
feedback were encouraged. Fieldnotes of these were taken.

3.10.3.1.2 RACF nurses
In two RACFs, RNs were interviewed one-to-one using the semi-structured interview
questions (Appendix 9). In a third RACF, other nurses with a role in warfarin administration
also participated in evaluation in a group setting. For this RACF, written answers were
provided by the participants anonymously, followed by an interactive session where
feedback based on the questions was encouraged by the researcher. As there was a range in
the role of the nurses in medication management, not all respondents from all RACFs
answered all questions. Fieldnotes for all interviews and the group interactive session were
taken.

3.11 Data analysis
The data collected throughout the study were quantitative and qualitative (O'Leary 2004).
Descriptions of the methods of data analysis are provided in the sections immediately
following.
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3.11.1 Outcome data: Indicators of quality use of warfarin
Quantitative resident data were analysed to assess some indicators of the quality use of
warfarin, so that comparisons of these outcomes could be made from before the
intervention in phase 1 (pre-test) with after in phase 3 (post-test). The data utilised were the
INR results and warfarin doses and were analysed according to the following indicators:

•

the frequency with which the INR spends in the therapeutic range (TTR) (calculated
using the method known as the “proportion of INRs in range” and presented as
percentages; that is, the percentage of INRs measured in the target range of the
total INRs performed for a given period (Scmidtt, Speckman & Ansell 2003; Witt
2011)) The number of times INRs were recorded below, within or above the
therapeutic range in phase 1 was compared to phase 3 (after the intervention) and
p- values were calculated using the Fisher’s exact test.

•

documentation of extreme INR values (as proposed in the literature (van Walraven,
Oake et al. 2007) as an INR greater that 3.0)

•

dosage alterations of warfarin in response to INR (advised in Australian clinical
guidelines to occur if the INR is above target (Baker et al. 2004) or if the INR is above
4.0 in other healthcare quality indicators (NSW Therapeutic Advisory Group 2007)).

These quality indicators are consistent with those identified in the literature and are
surrogates for the safe use of warfarin, as discussed in Chapter 2. They also are able to be
measured within the constraints of using secondary data sources. For the purpose of this
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study the quality indicators were compared using descriptive statistics only as the
population characteristics of the pre-test and post-test populations were not matched
before and after intervention.

Baseline resident data collected related to quality use of warfarin, as outlined in 3.10.1.2,
were the number of recordings of indication for warfarin as well as the target INR. The data
from phase 1 and phase 3 were compared and p-values calculated using Fisher’s exact test.

Other resident data collected were used to provide an analysis of additional indicators of
quality use of warfarin; in particular
•

potentially inappropriate drugs used concurrently and

•

warfarin-related adverse drug events

The definitions used for these are given in the sections immediately following.

3.11.1.1 Concomitant medications and potentially inappropriate drugs
The definition of a concomitant medication used was one that was administered either from
a GP’s order or was “nurse-initiated” and included regular, prn and short courses of
medications. All concomitant medications documented in the residents’ medication charts
were recorded and grouped into medication groups, if appropriate, or as the individual
agents. The percentage of residents receiving the medications or medication groups was
calculated and those administered most commonly to residents were tabulated.
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The number of regular medications used by each resident was totalled, along with the range
of medication use for the study group and the mean number. Using the definitions referred
to in the literature, the incidence of “polypharmacy” as five or more (le Couteur et al. 2004;
Shi, Mörike & Klotz 2008) or nine or more medications (Nguyen et al. 2006) was calculated.

The definition of a potentially inappropriate drug combination with warfarin was based on a
compilation of medications known to interact with warfarin from several references
(Greenblatt & von Moltke 2005; Holbrook et al. 2005; Ghiculescu & Pillans 2008; Verhovsek
et al. 2008; Wallerstedt et al. 2009; AMH 2011; Zhang et al. 2011). As with most
pharmacokinetic drug interactions, the impact on either of the medications will be mainly
obvious when one or both are being commenced, with dosage adjustment, if the use is
intermittent, if there has been a change in a characteristic or factor within the patient, or
when being ceased. If the two medications have been stabilised, the risk of a clinically
significant interaction is minimised. For some interactions however, for instance
pharmacodynamic, this risk is not minimised with stable dosing; such in the case of warfarin
with antiplatelet medications. All medications with the potential to interact were noted. In
addition, possible or probable clinically significant events, defined as those actual warfarinrelated adverse events that occurred and were temporally related to the addition or
deletion of the interacting medication, were recorded.

3.11.1.2 Warfarin-related adverse events
All warfarin-related adverse events referred to in the medical records of the residents were
recorded by the researcher. As outlined in the literature review, these included those that
had the potential for an adverse outcome (an INR above the target range) (Gurwitz et al.
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2000) and those in which an actual haemorrhagic event was recorded (Gurwitz et al. 2007).
Although the risk of haemorrhage is intrinsic to its mechanism of action, warfarin as the
causative or contributory factor was not always able to be established. As an INR above 3.5
is independently associated with an increased risk of intracranial haemorrhage in this older
population (Fang et al. 2004), this was the INR value taken for the purpose of this study, as
defining a potential warfarin-related adverse effect.

Actual warfarin-related adverse events recorded in the literature are often adjudicated and
graded according to severity. In higher quality research, it is desirable that definitions are
provided and consistent for all severity gradings (Wyse 2007; Hylek & Magnani 2008). The
events recorded by the researcher in the present study relied on secondary data sources
and were collected retrospectively; hence any grading with accuracy was beyond the scope
of the study and not attempted.

3.11.2 Analysis of semi-structured interviews
Semi-structured interviews with participant GP and RACF nurses in phase 3 provided data
from both the closed and open-ended questions. Closed-ended questions were analysed
using descriptive statistics. For the open-ended questions and closed-ended inviting further
comment, respondents were allowed to put answers into their own words. This questioning
was useful as the responses were unknown prior to the questioning and were then analysed
with thematic exploration. As well as the student researcher, a post-doctorial academic,
with no connections to the research, additionally analysed the content of responses from
the RNs and GPs for common themes. As the questionnaires were predominantly selfadministered, the thematic analysis process employed was exploration of words (O'Leary
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2004d). Saturation of themes was not attempted as there were a limited number of
respondents: however these are representative as they comprised the whole of the sample
of those healthcare providers who had been users of the management strategy.

3.12 Summary
In summary, this chapter has described the mixed-methodology approach employed in the
study, utilising a pre-test/post-test with intervention design. Descriptive statistics were used
to assess the quality indicators of anticoagulation and also the acceptance and usability of
the warfarin management strategy. Additionally, thematic analysis of GP and RN participant
interviews was used to evaluate the strategy.

77

4 FINDINGS
4.1 Introduction
This chapter will report the findings of the study and how they relate to the research aim. As
described in the previous chapter, the aim of the research was to evaluate the acceptance,
usability and safety implications of the implementation of a warfarin management strategy,
using a warfarin-specific medication chart in residential aged care facilities providing highlevel care. The findings of the research will be detailed in chronological order of collection
and analysis of the data, according to the three phases of the study.

4.2 Phase 1 (pre-test phase)
4.2.1 Participants
Three RACFs participated in the whole study, with nine visiting GPs and a total number of 23
residents. The overall numbers of study participant RACFs, GPs and residents prescribed
warfarin are shown in Table 4-1. The numbers of RNs and other nurses from the participating
RACFs are detailed later in this chapter in section 4.3.1.1 in the details of the warfarin
education sessions which occurred in phase 2, and in the findings of semi-structured
interviews in 4.4.4.2 which occurred in phase 3.

4.2.1.1 RACFs and nurses
The managers of five RACFs returned expressions of interest in participating in the study. As
indicated in Table 4-1, three RACFs only (A, B and C) eventually contributed to all phases of
data collection as one manager chose to adopt the charts outside the parameters of the
study and another did not continue due to staff changes. A senior RN from a sixth RACF (D)
expressed an interest in participating however recruitment of the large number of visiting
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GPs proved too difficult in the time-frame available. Staff in RACF D received warfarin
education only and did not contribute any further data.

Table 4-1 Participants in warfarin management strategy study
Participants

Total

RACFs (code)

Number of GPs prescribing
warfarin in each RACF*

Total number of residents
prescribed warfarin in study
period

A

5

9

B

3

5

C

6

9

3

9

23

* GPs visited more than one study RACF

4.2.1.2 GPs
Nine GPs with patients as residents in RACFs A, B and C participated in all phases of the
study. (There were eleven GPs in total visiting participant RACFs with patients on warfarin;
one did not supply consent to participate and the patient of another (GP Code B) had
warfarin ceased prior to the intervention [phase 2]). The number of participating RACFs and
residents visited by each GP is recorded in Table 4-2. These statistics were mainly derived
from the closed questions of the semi-structured interview in phase 3; however they are
presented now as the GPs were recruited and involved from phase 1. The details in Table 4-2
also provide an indication of the range of involvement in residential aged care in the
Illawarra of the participating GPs; four GPs had only one patient receiving warfarin in
residential care, whereas one GP visited all three RACFs, cared for ten patients in the study,
had another three patients receiving warfarin in other RACFs and visited a total of 50
patients as residents across all Illawarra RACFs.
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Table 4-2 Participant GPs, the study RACFs and residents (and other Illawarra RACFs) visited by the GPs

GP code

Number of study
RACFs visited by
GP

Number of patients as
residents across all
Illawarra RACFs

Number of patients of GP
prescribed warfarin
across all Illawarra RACFs

Number of patients
of GP prescribed
warfarin in study
(study residents)

A

2

60

10

4

B*

1

NR

1

1

C

3

50

13

10

D

1

50

6

1

E

2

50

6

3

F

1

14

2

1

G

1

NR

NR

1

K

1

8

1

1

O

1

11

1

1

P

1

NR

1

1

Total GPs
contributing to
data = 9

Range= 1 -3

Range = 8 - 60

Range = 1 - 13

Range = 1-10

*GP Code B had one patient as a study resident; this resident had warfarin ceased during phase 2; GP Code B
and resident did not contribute to any further data after phase 1.
NR = not recorded

4.2.1.3 Residents prescribed warfarin
There were 19 residents receiving warfarin from the beginning of the pre-test phase (phase
1.) Three of these had warfarin ceased before the intervention (phase 2) and a further four
residents commenced during or after phase 2. Thus a total of 23 residents contributed to
data: 19 from pre-test and 20 in post-test.
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4.2.2 Baseline retrospective resident data

4.2.2.1 Indication for warfarin
The indications for anticoagulation according to sources in the residents’ records, and the
incidence of each are graphed in Figure 4-1. The most common reasons why a resident was
taking warfarin were either “stroke” or “CVA” [sic] documented for nine residents, followed
by “AF” [sic] documented for eight. Differing warfarin indications and more than one
possible indication were sometimes documented. There were only nine cases in which the
prescriber had recorded the indication for warfarin. For three residents, any possible
indication was not able to be found in the resident’s notes at any time in the study.

Figure 4-1 Possible indications for warfarin from residents' notes*
CVA

cerebrovascular accident

AF

atrial fibrillation

PE

pulmonary embolus

DVT

deep venous thrombosis

TIA

transient ischemic attack

* More than one indication could have been listed
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4.2.2.2 Comorbidities and concurrent medications
The most commonly noted comorbid medical conditions are shown in Figure 4-2 and were
osteoarthritis documented for ten (43%), hypertension for ten (43%), “CVA” or “stroke” [sic]
for nine (39%) and falls (history of, or frequent falls) for nine (39%) of the 23 participant
residents. The range in the number of comorbid conditions recorded was 3 to 15 with a
mean of 8.3, as listed in Table 4-3.

Table 4-3 Range and mean of resident comorbid conditions, total regular daily medications and those used
concurrently with warfarin

Resident comorbid
conditions

Total daily regular
medications

Medications used concurrently
with warfarin

range

3 - 15

range

3 - 17

range 2 - 16

mean

8.3

mean

10

mean

9

Complete medication information was available for 22 residents. The medication or
medication group prescribed for the most number of residents are depicted in Figure 4-3
with paracetamol for 19 (86%) residents, the combined vitamins, minerals and electrolytes
group (excluding vitamin D) for 13 (59%), laxatives for 13 (59%)and antihypertensives for 13
(59%) the most common. The range of regular medications used (including warfarin) was 317 and the mean was 10, as per Table 4-3. Applying the definition of polypharmacy as five or
more medications (le Couteur et al. 2004; Shi, Mörike & Klotz 2008), 91% residents received
polypharmacy. If the alternative definition of nine or more medications is applied (Nguyen
et al. 2006), 68% of residents received polypharmacy.
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Figure 4-2: Comorbid conditions most frequently recorded

Figure 4-3: Medications used concurrently with warfarin for the most number of residents

Overall, 35 different medications or types of medications were prescribed concurrently with
warfarin. There were few changes to concurrent medications in the study period and so the
medications depicted in Figure 4-3 are those prescribed most commonly with warfarin at
any time over the three phases of the study.
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Additional medications were received by the residents in the form of short courses, or prn
(“pro re nata” or “when required”) medications. The most common short course or prn
medications were paracetamol and antibiotics. The potential for interactions and suspected
interactions with warfarin are discussed in later sections on quality use of warfarin (section
4.4.3.1).

When Figure 4-2 and Figure 4-3 are compared, there is a congruence in the medication
administered to the most number of residents (paracetamol, an analgesic used for
osteoarthritis) and the comorbidity (osteoarthritis) most frequently recorded. For some
concurrent medications the associated comorbidity was not noted; for instance,
antidepressants were prescribed for 11 (50%) of the residents with complete medication
data, although depression was not recorded as a condition for any resident. The one
resident receiving amitriptyline (an antidepressant which may be prescribed as an analgesic
in some instances) did not have pain diagnosis.

Other baseline retrospective resident data relevant for warfarin (documentation of the
target INR and indication for warfarin) collected in the pre-test phase (phase 1) are
compared to that collected after the intervention in phase3 (post-test) in sections 4.4.1 and
4.4.2.
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4.3 Phase 2 (intervention with education)
4.3.1 Warfarin education sessions

4.3.1.1 Participants in warfarin education sessions (“sessions”)
In total, 56 managers, nurses and care-staff participated in the warfarin education sessions.
The number of sessions and total participants are listed in Table 4-4. As shown in this table,
the majority of attendees were RNs, reflecting their role in warfarin management. The
sessions were repeated as described so that there was 100% attendance of RNs from the
three RACFs who participated for the total study duration. Some RNs attended more than
one session through their own choice and although their attendance contributed to these
numbers, they completed the warfarin questionnaire only once at the most (discussed in
following section 4.3.1.2). As mentioned previously in phase 1 findings (section 4.2.1.1),
although RACF code D did not contribute study data, one session of staff education was
completed.

Table 4-4: Participants in warfarin interactive education sessions
RACF code
A

Number of
sessions
2

RACF managers &
RNs (n)
13

EENs
(n)
3

B

4

11

4

C

4

13

1

D

1

4

3

Total

11

41*

11

RN = registered nurse

EEN = endorsed enrolled nurse

Other RACF
staff (n)
3

Other

Total
participants
19
15

1 area
manager

15
7

3

1

56

* RNs attended more than one session
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4.3.1.2 Warfarin questionnaires
From the 52 RNs and EENs who attended, 23 questionnaires were returned: a response rate
of 44%, although as stated, some RNs attended more than one session and completed the
questionnaire only once so the real response rate would be higher than this percentage. For
the first set of knowledge-based questions, the percentage of accurate responses is shown
in Table 4-5. Caveats were added by some respondents to some questions which were quite
reasonable and promoted discussion in later components of the education session. From
this table it can be seen that although there is a sound knowledge of warfarin, the influence
of food and other medications on the action of warfarin is not universal knowledge.

Table 4-5: Response accuracy to knowledge-based questions: factors with potential to impact upon the
resident receiving warfarin
Proposed scenario
Resident has diarrhoea

% accurate responses
(from 23 responses)
78

Resident has been vomiting

78

Resident is not eating

65

Resident has other medication(s) started in the past week

83

Resident has not been taking warfarin

96

Resident has had other medication(s) ceased in the past week

70

Resident has a new infection

78

Resident has not been taking other usual medications in the past week

61

From the responses to the second set of questions, the percentage of “ideal” answers is
shown in Table 4-6. As a corollary to the responses to the knowledge-based questions, dietary
changes or commencement of new medications were the situations least likely to prompt a
notification to the resident’s usual GP.
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Table 4-6: Ideal responses to process questions: action by nurse to contact GP in response to proposed
vignette in a resident receiving warfarin
Proposed scenario
Resident has diarrhoea

% ideal response
(from 23 responses)
91

Resident has been vomiting

91

Resident is not eating

74

Resident has other medication(s) started in the past week

78

Resident has not been taking warfarin

87

Resident has had other medication(s) ceased in the past week

57

Resident has a new infection

91

Resident has not been taking other usual medications in the past week

78

4.3.1.3 Interactive warfarin workshop
Fieldnotes taken from the 11 sessions recorded a variety of professional and clinical
backgrounds for the RNs including drug and alcohol, paediatrics or disabilities; relevant
information as there was a lack of warfarin knowledge admitted by some of the participants
and an appreciation expressed for the opportunity to update.

The prompt questions generated some recurring discussion points and consistent issues.
From the responses to the prompt questions, the overall knowledge of the action of
warfarin, the impact of dietary changes and potential for medications other than antibiotics
to interact (particularly prn paracetamol) and the valid indications for warfarin seemed
superficial. Generally, uncertainties existed about some nursing practices, for instance
crushing warfarin tablets, particularly if the dose was to be administered via percutaneous
endoscopic gastrostomy (PEG). Although it was appreciated that an INR result above a
target range was a prompt for remedial action, subsequent communication with GPs about
this or other possible warfarin-related matters depended on the experience of the RN and
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the perceived receptiveness of the GP. The interactive workshop provided an opportunity
for reflection; that is, the discussions arising from the prompt questions segued to analyses
of previous warfarin-related adverse events that had occurred in residents for whom the
nurses had cared.

4.3.2 Implementation of strategy and chart modifications
Open communications with the researcher by the RNs and EENs who were early users of the
chart in each RACF resulted in some early modifications once the strategy commenced and
the chart was used. These were:
•

the removal of shading from the administration record (designed originally to
delineate the weeks) and on heading sections, due to blurring and a loss of
transparency when faxed;

•

the removal of the section intended for the current dose to be transcribed from the
GP’s order immediately above, due to confusion as to its purpose;

•

the widening of columns to improve legibility of writing with faxing; and

•

a rearrangement of the GP alert section to function as a prompt for RNs (rather than
a limited space to provide details).

A copy of the final chart after modifications is reproduced in Appendix 10.
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4.4 Phase 3 (post-test phase)
Quantitative data and the analysis of quality indicators will be presented in this section,
followed by analysis of the semi-structured interviews.

4.4.1 Resident data
In collecting warfarin-relevant data, the disparate storage and filing systems of the RACFs
became obvious very soon into the study to the researcher, a clinical pharmacist with
experience in analysing medical notes and records. Information relevant to warfarin therapy
was found physically in five different places in one RACF alone. The following data is
presented with knowledge of those limitations.

4.4.1.1 Documentation of warfarin indication

The documentation of the indication for warfarin before the intervention (in phase 1) and
after (in phase 3) is depicted in Figure 4-4. Documentation improved from appearing for
nine (47%) of the residents in the pre-test phase, to 15 (75%) of residents in the post-test
phase, using the stricter definition of “documentation” for the post-test phase (phase 3);
that is, only that appearing on the chart, although the improvement was not significant
(p=0.11).

4.4.1.2 Documentation of target INR

The documentation of a target INR before the intervention (in phase 1) and after (in phase
3) is also depicted in Figure 4-4 . Documentation improved from appearing in only one (5%)
of the residents’ records in the pre-test phase (phase 1) to 15 (75%) in the post-test phase
(phase 3). The improvement in documentation was statistically significant (p<0.0001).
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Figure 4-4 Documentation of residents' warfarin indication and target INR during phase 1 (pre-test)
before the intervention and during phase 3 (post-test), after the intervention

4.4.2 Outcome data analysis: Indicators of quality use of warfarin

4.4.2.1 INR results and the TTR

The target range for INRs was taken as between 2.0 and 3.0 for all residents unless
otherwise explicitly stated by the prescriber, and for the one resident with an indication of
prosthetic heart valves it was taken as between 2.5 and 3.5 (as documented by the GP). The
TTR in the pre-test phase (phase 1) was 43% (33 of the 76 INRs performed). After the
intervention the TTR was increased in the post-test phase to 53%; that is, 42 of the 80 INRs
performed, although the increase was not significant (p=0.15). The percentage of INRs that
were supertherapeutic (that is, above the target range) was similar in both phases 1 and 3;
that is, 15 of 76 (18.5%) and 14 of 80 (17.5%) respectively (ns p=0.84). The percentage of
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INRs that were subtherapeutic (that is, below the target range) was reduced from 30 of 76
(39.5%) in pre-test phase (phase 1) to 24 of 80 (30%) in post-test (phase 3.) (ns p=0.32). The
percentage of INR results measured in the therapeutic range (TTR) and out of range is
depicted in Figure 4-5. It should be noted that the actual number of INRs performed differed
in the two phases; that is, there were 76 in pre-test phase (phase 1) and 80 in post-test
(phase 3).

Figure 4-5 Percentage of INRs spent in the therapeutic range (TTR), above the therapeutic range (TR)
and below TR in phase 1 (pre-test) and phase 3 (post-test)
(See text for definition of therapeutic range and number of INRs performed in each phase)

New admissions: additional findings concerning INR results and implications in quality
calculations
There were five new resident admissions to the RACFs in phase 3 (post-test phase). Four of
the INR results above target during this phase were measured in three new residents soon
after admission; all reportedly stabilised on a warfarin dose which had been continued in
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the RACF. This situation did not occur in phase 1 (pre-test phase) as the residents were all
considered “inception cohort” participants; that is already taking warfarin in the conditions
of the study (Hylek & Magnani 2008).

As discussed in the literature review, it has been proposed that those who are warfarinnaïve or have had interruptions in therapy or are subject to new conditions are prone to
labile INRs and that this should be considered in quality or outcome assessments (Ansell et
al. 2008; Witt 2011). Using the same rationale, if the supertherapeutic INRs of the new
admissions in the phase 3 (post-test phase) are removed from calculations, the percentage
TTR is increased to 55% (42 of the remaining 76 INR results), although this was still not
significant (p=0.19). Also, the percentage of supertherapeutic INRs in phase 3 (post-test
phase) is reduced to 13% (10 out of 76) (ns. P=0.38). The changes to TTR and percentage of
INRs above the target range are depicted in the third columns of the two groups in Figure 4-6.

Figure 4-6: Percentage of INRs spent in the therapeutic range (TTR) and above the therapeutic range when the
INR results of new admissions in phase 3 (post-test phase) are excluded.
See text for definition of target range and the numbers of INRs performed per phase.
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The INR details of the three new resident admissions with results above target are tabulated
in Table 4-7. (Nominal codes have been applied to the residents in this table).

Table 4-7: INR results and outcomes for new resident admissions to RACFs in phase 3 whose first INR results
were above target range

Resident

INR result (days after admission)
when resident continued on same
warfarin dose as prior to admission

Outcome

1

INR = 3.7 at 14 days

warfarin withheld and dose reduced;
next INR = 3.2 after 4 days

2

INR = 4.9 at 9 days

warfarin withheld and dose reduced;
next INR in target range

3

INR = 4.2 at 5 days

warfarin withheld and dose reduced;
next INR in target range

4.4.2.2 Extreme INR values
The number of extreme INRs recorded (INR above 3.0 as per definition) was 15 out of 76
(18.5%) of all INRs in the pre-test phase (phase 1) and 14 out of 80 (17.5%) in post-test
phase (phase 3), as depicted in Figure 4-5 and discussed in the previous section.

4.4.2.3 Dosage alteration in response to INR
Comparisons were made between the warfarin dosage responses to INRs that were out of
target range, or aberrant, that occurred in pre-test (phase 1) before the intervention with
those of post-test (phase 3), after the intervention. For this comparison it was possible to
use three individual resident’s data, as these residents had aberrant INRs in both phases of
data collection. Table 4-8 compares the actions by GPs for the three residents; their
nominated GP remained the same in both phases. (Nominal codes have been applied to the
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residents in this table. They are not the same residents as in Table 4-7.) For these three
residents, the quality of warfarin as assessed by appropriate dosage adjustment was
improved after the intervention in phase 3, the post-test phase.

Table 4-8 Response to three resident's aberrant INR results: in pre-test (phase 1) before the intervention and
in post-test (phase 3), after the intervention.

Resident

Phase 1: action following aberrant INR
results (pre-test)

Phase 3: action following aberrant INR
results (post-test)

1

Four INR results > 3.0 over 9 weeks without
warfarin dosage change

Four INR results > 3.0 over 3 weeks with
subsequent warfarin dosage reductions

2

Subtherapeutic INRs without warfarin dosage
change

Two INR results out of target with associated
dosage change

3

INR > 3.5 without warfarin dosage change;
RN withheld warfarin until GP’s orders received
after next scheduled dose was due

INR > 3.5; dose reduced immediately by GP
after faxed chart was received

Throughout phase 3 (post-test phase), there were a further four INR readings above 4.0 in
other residents and two above 3.5. In five of these six cases the action was immediate and
appropriate and was to order a temporary suspension of warfarin and a subsequent dosage
adjustment.

4.4.3 Other quality use of warfarin indicators

4.4.3.1 Concomitant medications and potentially inappropriate drugs
There were 13 medications or medication groups with a potential for drug interactions with
warfarin administered to 21 residents on 45 occasions throughout the study (with a range of
1 – 4). That is, for those for whom complete data was available, 91% received at least one
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medication concurrently with the potential to interact with warfarin. These are listed from
the most common to least common concurrent administration in the first column of Table
4-9.

The second column of Table 4-9 lists the eight medications whose concomitant use with
warfarin resulted in a clinically significant outcome, possibly or probably due to the
interaction in 16 instances; that is, 36% of the times interacting medications were used. The
only anti-platelet agent administered concurrently to any resident in the study was aspirin
for two residents: both had hospital admissions due to gastro-intestinal haemorrhages.
Table 4-9: Concomitant medications with potential and actual drug interactions

Concomitant medications with potential for
drug interactions with warfarin
(most to least commonly used)

Concomitant medications administered
with resultant clinically significant
outcomes, possibly or probably due to the
interaction

prn or new order for regular paracetamol

paracetamol

atorvastatin

aspirin

citalopram

vitamin K (in nutritional supplement)

omeprazole

omeprazole

sertraline

simvastatin

rosuvastatin

amoxycillin+/-clavulanic acid

amoxycillin

thyroxine

thyroid hormone (thyroxine) or

amiodarone

anti-thyroid (carbimazole)
vitamin K (in nutritional supplements)
aspirin
simvastatin
amiodarone
amoxycillin with clavulanic acid
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From the pre-test phase (phase 1) to post-test (phase 3) there was no apparent difference in
the occurrence of administration of concomitant potentially interacting medications.
However, after the warfarin education sessions, there were individual examples where a
change of practice occurred at the initiation of the RNs who had attended. These were:

•

three residents who had been receiving paracetamol intermittently by RNs as
“nurse-initiated” doses, had regular paracetamol prescribed by the GP on the
request of RNs;

•

the GP of a resident was notified of a new order for antibiotics that had been
prescribed prophylactically by a cardiologist for pacemaker replacement;

•

the administration time of warfarin for a resident receiving warfarin via a PEG was
altered to coincide with the scheduled pause in the nutritional feeds to reduce the
potential for a warfarin and enteral feed binding interaction (Dickerson 2008) o INRs documented for this resident in the pre-test phase (phase 1) before the
education sessions had fluctuated by 2.6 with an average INR of 2.0. The
range of fluctuation in the post-test phase (phase 3) was reduced to 1.1 and
the average INR increased to 3.0. (The warfarin dose was being reduced at
the close of the study in response to the increasing INR values).

4.4.3.2 Warfarin-related events
In total, there were 21 potential or actual warfarin-related adverse events documented to
have occurred in 13 residents; that is, in 57% of resident study participants. Throughout the
study the INR was documented above 3.5 (pre-defined as potential warfarin-related adverse
event) on 13 occasions; six of these were above 4.0.
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There were 13 actual adverse events (haemorrhages) in which warfarin had a causative or
contributory role that occurred in 9 residents; that is, 39% of resident study participants.
Five of these 13 actual events (39%) occurred when the INR was above 4.0. Also, of the six
occasions when the INR result was documented above 4.0, five episodes of bleeding
occurred. That is, while 39% of all haemorrhages occurred when the INR was above 4.0, in
83% of occasions when the INR was above 4.0, a haemorrhagic event was recorded. All
potential and actual warfarin-related events are listed in Table 4-10.

Table 4-10 Potential and actual warfarin-related events in residents during study
Outcomes: individual residents with actual
Residents’ INR results

warfarin-related adverse events
anaemia
hospital admission for confusion and falls: chronic bilateral subdural haematomas

INR between 2.0 – 3.5
or unknown at time of
event

low haemoglobin, low iron, malaena, hospital admission- hemicolectomy
malaena, Hb 66g/L, hospital admission, malignancy

(eight occasions)
urogenital bleed (three occasions)
gastrointestinal tract bleed; hospital admission

INR 3.5- 4.0

no documented clinical outcomes

(seven occasions)
upper gastrointestinal tract bleed, malaena, Hb 67g/L, INR 6.6; angina
INR greater than 4.0
(six occasions)

bleeding oedematous legs
haematuria
rectal bleed (two occasions)

TOTAL actual or
potential adverse
events = 21

Total actual (clinically significant) events = 13
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For many of the above warfarin-related events, multiple well-accepted causes were
possible. In two cases, both occurring in phase 1 (pre-test phase), the most obvious cause
was the result of well-documented, predictable drug interactions (de Luise 2003; Campbell
2005). In one of these, warfarin was recommenced at the dose previously prescribed for a
resident for whom it had been ceased due to a gastrointestinal haemorrhage; however
amiodarone and aspirin had been commenced in the interim. Prior to the next scheduled
INR test being performed, this resident required hospitalisation for management of a
further gastrointestinal haemorrhage, high INR, low haemoglobin and angina. For another
resident, doses of thyroxine were increased gradually over a period of a month without an
increase in monitoring of the INR; the subsequent INR was substantially increased.

4.4.4 Analysis of semi-structured interviews
Descriptive analysis of the closed-ended questions will be provided first, and then thematic
analysis of those open-ended questions that invited commentary from both GPs and RNs
will be presented.

4.4.4.1 General Practitioners
Nine GPs participated in final semi-structured interviews. Prior to commencement of the
study, the majority of dosage adjustments for warfarin were done over the phone, either
personally or by the receptionist (or their “girls”) or practice nurse. Only two GPs responded
that they had previously utilised the fax.

98

Figure 4-7: GP responses to closed questions: usability and acceptance of warfarin medication chart

For the questions to evaluate usability and acceptance of the charts, the responses are
depicted in Figure 4-7. The majority of the GPs (eight of the nine or 89%) found that
compared with before the intervention, the charts saved time and enhanced
communication, and seven of the nine (78%) found warfarin easier to prescribe. There was a
unanimous vote for ease of use and for widespread adoption of the strategy and charts
throughout RACFs.
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4.4.4.2 RACFs nursing staff
Semi-structured interviews were undertaken with 15 nurses, 12 of whom were RNs. Not all
participants responded to all questions as this depended on their role in warfarin
management. For the questions to evaluate usability and acceptance of the charts, the
responses are depicted in Figure 4-8.

Figure 4-8: RN responses to closed questions: usability and acceptance of warfarin medication chart

Eight of the 14 who responded (57%) answered that the charts saved nursing time; the
remaining six responded that they took the same amount of time but provided more
information. Five of the nurses 13 responding (39%) answered that the charts enhanced
communication, seven respondents (54%) - all from the same RACF- responded that
communication was the same. The remaining one answered that communication was the
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same but there was more information provided. Of the 12 who responded, 10 (83%)
reported it was easier to find the warfarin dose Twelve of 13 who responded (92% ) found
the charts easy to use with the remaining response being the chart was hard to use at first
but she “had got used to it”. All 12 who responded agreed that the charts should be
adopted; although one (an RN) provided caveats.

Of the nurses, only the RN participants provided feedback in the open-ended part of the
semi-structured interview, and their responses are discussed in the following section on
thematic analysis, along with those from the GPs.

4.4.4.3 Thematic analysis of semi-structured interviews: GPs and RNs

4.4.4.3.1 Major themes
Ten themes have been garnered from analysis of the semi-structured interviews and
feedback that was encouraged by the open-ended questions to the GPs and RNs. These
have been grouped and presented below, with exemplar quotes from both disciplines
reproduced, as applicable. The code for the respondent and the page number (p) from the
fieldnotes (FN) are supplied.
(i)

Essential information

The features of the chart that eased the role of the prescriber were praised. Generally, the
availability of the information required to make a prescribing decision off-site, as provided
by the “flow-chart” was touted as an advantage:
“The last dose that the patient has been taking is there as well and that is important
when prescribing the new dose”

(GP code K; FN p2)
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Similarly, the RNs appreciated having this information:
“Now we are able to know old and current INRs and warfarin value [sic]”
(RN code B1, FN p4)

(ii)

Time saving

The saving of time was a repeated commendation of the strategy, mainly by the GPs.
“It is great; everything is there- it saves time! I can give instructions that the RN will
get without having to ring”

(iii)

(GP code E, FN p3)

Workflow improvements

Improvements in workflow as well as being time-saving (as described above) were the
advantageous features most commonly voiced by the GPs. The following quotes could well
relate to other themes such as improved documentation; for instance:
“In...(facility name) everything is working really well; I receive the fax and can
respond when it is convenient. The other will improve when they get more used to
not ringing up- I have to remind them to fax the chart and not ring for the dose.
…Most phone calls are now eliminated. I’m not getting as many interruptions. I can
get to it in between my patients”

(GP code C, FN p3)

“There is clear documentation; this keeps the GPs on their toes (AND us nurses); you
can see everything easily and straight away”

(RN code C4, FN p6)

Improvements to workflow potentially have the flow-on effect of reducing overall
medications error rates, if interruptions are reduced.
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(iv)

Repetition removed

Previous methods of recording variables and prescribing warfarin involved multiple entries
in various sites (physical and electronic). Both disciplines nominated the streamlining of
records as a valuable consequence of using the strategy:
“There is no doubling up with work; providing all the information that is needed to
decide the dose on one sheet”

(GP code O, FN p2)

“Probably the same communication as before, but we used to have to write out more
details, a fax cover sheet. Now it is all in one spot; and more succinct and easier”
(RN code C4, FN p4)
In facility Code C, prior to the implementation of the strategy, warfarin-relevant information
was found in five different places in the pre-test phase (phase1). Removing repetition and
transcribing was noted by many respondents as potentially reducing a source of error.

(v)

Enhanced communication

Optimal warfarin management relies on ideal communication occurring between all those
who are responsible, especially as the RNs are acting in an emissary role for the high-level
care residents prescribed warfarin. Improvement in communication was dominant feedback
from the RNs and also a feature of some of the GP feedback.
“When I was ringing them before, I was not sure if the message would get to the RN”
(GP Code K, FN p1)
“There is space to write resident changes for the GP; current and old INR and
warfarin-it is more informative”

(RN Code A5, FN p6)

and
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“I used to just book in the INRs for [the resident] of Dr…..... but now he says when he
wants it to be done.”

(vi)

(RN Code A3, FN p5)

Certainty/confidence

The certainty that the dose to be administered was current and that this was now easier to
find with the new strategy, was commended by RNs.
“… it used to be when they [the GPs] come in next they would write up the order
which could be months. It is easier to see when there has been a change compared to
the old sign-on sheets”
(RN Code B3, FN p6)
“…[there are] more current orders; doses are reviewed and dosage changes
occurring”

(RN Code C1, FN p5)

This last comment provided anecdotal support to the findings documented in section
4.4.2.3; that is for at least three residents for whom there was comparative information
available, doses were changed in a timely manner.

(vii)

Error reduction

Some GPs proposed that the strategy could reduce errors and two examples of error
identification were noted by the RNs.
“Good to see changing doses and as a check of pharmacy dispensing; better for team
leaders as they can see what dose should be there. Normally she just gives what is in
the (Webster) pack and signs it on the “sign-on” chart. With the new charts, she saw
what was packed dose was not what the doctor prescribed and asked me about it”
(RN Code B3, FN p6)
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and
“Because you write down what dose you are giving, we could see that the wrong
dose was given the night before”

(viii)

(RN Code A2, FN p4

Improved documentation

The value in having a documented dose and clear place for signing the actual dose given was
a repeated accolade of the chart from the RNs
“There is a clear month for signing; not like the old sign-on charts where the dates
are hard to find”

(RN Code C3, FN p6)

Criticism of the previous system which used “sign-on” charts generated on dispensing was
given from RNs of the two RACFs which had previously used this system.

(ix)

Clear doctors’ orders

On a similar theme to the previous one, the most common feedback from RNs was that the
chart enabled them to administer a medication – in this case warfarin - from an actual
doctor’s order. That the order was not transcribed and was immediately adjacent to the
administration details they notated with dose, date and signature was highly praised. GPs
also appreciated the value of providing a clear order:
“I can provide written instructions on how to adjust the dose”
(GP Code C, FN p2)
and
“The order is there and has to be signed by the doctor”
(GP Code F, FN p2)
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“I like it as you can see that it is all there…it is an improvement as we are signing on
the same page as doctor's order without transcribing”
(RN Code C2, FN p6)
This feature promoted much informal discussion as to the advantages and disadvantages of
the changes to medication charting in residential aged care that had occurred throughout
the professional lives of the RNs.

(x)

Systemised approach

This theme was generated from feedback from those respondents with the most experience
in medication management in the residential aged care setting. The quote, “A brilliant little
system!” was from a GP (GP code C, FN p3) who had 10 patients as resident participants in
the study, and also treating 50 patients across all Illawarra RACFs at the time of the semistructured interview. A senior RN with a major role in co-ordinating INR testing and
following up warfarin doses with GPs had, during the education sessions in phase 2,
pronounced that the strategy would be “a pain in the bum” in her opinion. During the posttest phase (phase 3), this RN became a vocal advocate for the strategy and during feedback
declared:
“I love it!”

(RN code C4, FN p6)

Perhaps one of the most telling comments came from a senior RN in one facility.
“There are people in here who, before these charts, hadn’t had a written warfarin
order for years!”

(RN code C1, FN p6)

and this from a GP
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“When people are on warfarin in nursing homes, you never know when their INR is
going to be done; then you get the result and you don’t know what has been
happening to them and you don’t know what dose they’ve been on and you’re not
sure what it means…… this new chart helps you know all of that.”
(GP code I, FN p3)

4.4.4.3.2 Summary: thematic analysis
To collate these ten themes further, the three overall major themes were that the warfarin
management strategy and warfarin-specific medication chart:
1. more accurate documentation and clearer communication with a systemized
approach to enhance safety;
2. recognition of and delineation of roles of the those involved in warfarin
management; provision of certainty and confidence
3. time-saving; efficiency; work-flows enhanced.

As well as the best feature of the chart, the GPs and RNs were asked what they thought was
the worst feature. Some of these “features” had been dealt with over the duration of the
study, and have been referred to earlier in section 4.3.2. The GPs offered nothing new when
these questions were posed (although one did mention he would prefer if it was all
electronic and done via email). From the RNs’ perspective, that the time of the chart
expiring and the occurrence of new INR and review of warfarin dose did not coincide
provided difficulties. This observation had been made throughout the study. Further
enhancements to the chart were made in response to this at completion of the study in an
effort to minimise these glitches. The final chart is Appendix 10.
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4.1 Summary: study findings
In total, nine GPs, 23 residents, and nursing staff from three Illawarra RACFs with varying
organisational structures took part in the study. All potential GPs except one who could
have participated, provided consent; thus all possible residents except one participated.

Data analysis demonstrated improved outcomes related to the quality use of warfarin when
the data from the post-test phase (phase 3) were compared to that of the pre-test phase
(phase 3). The other quality indicators of adverse events and drug interactions did not differ
obviously throughout the study. Thematic analysis of feedback provided by the GPs and RNs
was that the strategy provided more accurate documentation of essential information,
formalisation of the roles in warfarin management, reduced time and improved workflow:
all with the potential impact on improving the safety of warfarin; indeed, medication errors
were discovered as a result of the strategy.

The availability and openness of the researcher to modifications resulted in a warfarin
management strategy and chart that had unanimous votes for acceptance. This chapter
demonstrated the acceptance, usability and safety implications of the warfarin management
strategy in three Illawarra RACFs.
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5 DISCUSSION
The findings of the study on the introduction of a new warfarin management strategy into
three Illawarra residential aged care facilities are highly promising and demonstrate the
usability, acceptance and potential safety implications of the intervention. The key findings
of the study will be discussed in this chapter and related to previous research.
Recommendations for future research will be made based on the overall study outcomes.

5.1 Usability and acceptability of warfarin management strategy
A warfarin-specific medication chart that functioned as a prescription, monitoring and
administration record was inherent to the warfarin management strategy. Its usability and
acceptance were evaluated with qualitative and quantitative data generated from those
directly involved with using the chart: the GPs with patients as residents and the nurses
involved with warfarin management. On all measures, there was either a unanimous or
majority vote for the chart from GPs and nurses compared to previous individual practices in
the RACFs, based on ease of use, ease of finding the current dose of warfarin and time saved
in warfarin management. Communication was either similar or enhanced compared to
previously used methods. There was a unanimous vote by both disciplines for the strategy
to be adopted by all participants from all three RACFs.

From analysis of the qualitative data, acceptance for the strategy was also demonstrated by
the stated preference over previous methods of warfarin management, grouped into three
overarching themes.
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1. more accurate documentation and clearer communication with a systemized
approach to enhance safety;
2. recognition of and delineation of roles of the those involved in warfarin
management; provision of certainty and confidence
3. time-saving; efficiency; work-flows enhanced.

The first theme to emerge included the feedback from the RNs that a clear doctor’s order
was desirable. This was an unexpected but arguably major finding and reflected a broader
medication management issue in residential aged care, an industry currently apparently
uncontrolled by medication administration legislation. Prior to 2004 when the NSW Nursing
Home Act was repealed (NSW Health 2004), medication administration in nursing homes in
NSW was directed by the NSW Health Pharmaceutical Services Branch document which
stipulated:
A medication chart in a nursing home should be so designed that it
provides…adequate space, in the one document, for the following to be
recorded:…record of administration of each dose of each medication, directly
adjacent to the medical practitioner’s medication orders. The record of
administration must be signed (initialled) by the administering person, showing the
date and time of administration
Clauses 57, 119, P & TG Regulation 2002.
Clause 44, Nursing Homes Regulation 1996
(NSW Health 2003)
Currently, medication administration in residential aged care in Australia is under the
auspices of Commonwealth Government. The relevant manual stipulates for Standard 2.7:
Medication Management that, ‘Residents’ medication is managed safely and correctly’
(Commonwealth of Australia 2009 p. 55) and refers to the Quality of Care Principles 1997
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(Australian Government 2010). The accreditation agency responsible for overseeing the
standards imposes no prescriptive frameworks for medication charts or the necessity of
referring to an original prescriber’s order (Aged Care Standards and Accreditation Agency
Ltd), and although these standards are currently under review, the draft changes do not
refer to this issue. Guidelines for medication management in this setting also do not provide
specific details (Australian Pharmaceutical Advisory Council 2002). The focus of the feedback
from the RNs specifically was the protection that previous legislation provided, but is now
non-existent.
To elaborate on this feedback from RNs, two of the three study RACFs utilised a medication
management system wherein the prescribers’ orders were transcribed by the dispensing
pharmacy and an administration sheet electronically generated, ostensibly to improve
legibility and allow for administration and signing by staff other than RNs or EENs. For
warfarin, a specific yellow “signing sheet” was generated and provided, although besides
the resident demographics other details were absent, notably the current dose of warfarin
and a date. This was the system that the study chart had replaced; hence the
commendations provided in RNs’ feedback. The chart was also responsible for the discovery
of two warfarin medication errors which would have not been possible with the system
previously used. Vogelsmeier et al. (2007), in their research into barriers to safe medication
use in five US nursing homes and key informant interviews, found similar unease as voiced
by the RNs in the current study, as they specifically highlighted concerns with transcribing
and the communication of the complex and frequent medication changes.

The hospital-based approach to prescribing and administering of medications in Australian
RACFs has changed over recent years without published evaluation of the mechanisms now
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used instead. Although the medication management system of transcribing and dispensing
of medications widely used in RACFs was presumably developed to enable safer
administration by staff with minimal qualifications, no published results of audits,
acceptance, usability or safety of these systems was found despite a thorough and specific
search of Australian literature. Over a similar time-frame, changes have also been made to
the medication charts used in Australian hospitals by the introduction of a standardised
National Inpatient Medication Chart (NIMC), created due to a recognised need to enhance
safety (Australian Commission on Safety and Quality in Healthcare 2011a). A review of this
innovation has been published (Millar et al. 2008): indeed, this was the only literature
retrieved concerning medication charts in an Australian healthcare setting. The conclusions
of one such research study was that the NIMC was inferior to that replaced – at least for one
major hospital - thus providing valuable feedback to the innovators. A similar project to
standardise the medication chart for residential care is currently underway (Australian
Commission on Safety and Quality in Healthcare 2011b), although without accompanying
legislative changes, the problems of transcription, as highlighted by the RNs in the current
study, will not be eliminated.

The second major overarching theme to emerge from the qualitative feedback also
supported the preference of the strategy over previous methods, as there was a clearer
delineation of professional roles. With recognition of specific roles in the medication
process, communication of warfarin-relevant information, monitoring and prescribing were
enhanced. These were relevant and important findings as they directly responded to major
barriers to quality use of warfarin voiced by both GPs and RNs interviewed in the previous
study that was the impetus for the present one (Jordan & Mullan 2008). Similarly,
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assessment of qualitative data from nursing home staff in the international literature has
nominated communication of orders, monitoring and the roles of the “team” as barriers to
quality use of medicines generally (Vogelsmeier, Scott-Cawiezell & Zellmer 2007; Barber et
al. 2009).

The third major theme to emerge from the qualitative feedback supported the strategy as it
reduced the time taken to manage warfarin by providing a format for recording necessary
information, improved workflow and reduced interruptions. This, in addition to the
feedback included in the first theme could potentially enhance the quality use of warfarin by
providing decision-support; for warfarin, at the time and place when the warfarin dose was
to be reviewed and prescribed. These results are positive ones, considering research
findings in the literature; that is, poor decision-support mechanisms for both prescribing
and administration of medications have been recognised as potential barriers to quality use
of medicines in nursing homes (Vogelsmeier, Scott-Cawiezell & Zellmer 2007). Also, the
safety of other medications could potentially be enhanced due to fewer interruptions to
workflow, as an observational study of drug errors in nursing homes demonstrated that
although RNs gave the least amount of medications they had more interruptions and a
similar drug administration error-rate compared to staff with lower credentials (ScottCawiezell et al. 2007). In that particular study, the RNs primarily administered more
specialised medications. This was similar to the role of the RNs in the present study, as in
questions in the semi-structured interviews the RNs responded that their main medication
roles were in the administration of more complex medications including insulin, warfarin,
opioids and administration via PEGs. The finding in the present study therefore, that the
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strategy reduced interruptions and improved workflow, is beneficial especially given the
ramifications of repeated interruptions to the RNs’ specialised workload.

5.1.1 Evaluation summary: usability and acceptance
Analysis of quantitative and qualitative evaluation data supported the acceptance and
usability of the new warfarin-management strategy, by those who are involved in warfarin
management in residential aged care. Additionally, the strategy was preferred over previous
methods and was recommended for broader adoption.

5.2 Safety implications of intervention of warfarin management strategy
The safety implications of the strategy introduced in the present study were assessed using
outcome measures. The measures used were surrogate markers of anticoagulation,
indicators of quality use of warfarin and clinical outcomes.

5.2.1 Safety implications: surrogate measures of quality use of warfarin:

5.2.1.1 Time in therapeutic range
The intervention employed in the current study resulted in a trend towards an improvement
in the surrogate markers of the percentage of TTR. Although there was a seeming
improvement in TTR (and concomitant small reduction in INRs above the target range), the
overall final TTR of 55% was still quite low when compared to the ideal, regardless of the
method of calculation used and despite acknowledged difficulties of comparing TTRs across
the literature (Scmidtt, Speckman & Ansell 2003; Ansell et al. 2008; Phillips & Ansell 2008).
As discussed in the literature review, a TTR above 65% (Connolly et al. 2008) or 70%
(Morgan et al. 2009) is desirable for optimal therapeutic benefits from warfarin and
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avoidance of haemorrhagic complications. However the TTRs achieved in studies of cohorts
of residents receiving warfarin in nursing homes have reported similarly low results as that
achieved in the current study: from just under 50% (Gurwitz et al. 2007), to 54% (Verhovsek
et al. 2008) and 55% (Aspinall et al. 2010). These poor results provide an indication as to the
lability of this older patient population and the difficulties in achieving quality
anticoagulation in this setting, and by extrapolation, raise concerns of exposure to possible
warfarin-related adverse events as well as to subtherapeutic levels with the associated
potential reduction in benefit.

Considering the surrogate measure of the INR employed as an indicator of quality use of
warfarin, one unforeseen finding was that the first INR results of the majority of new
admissions to the RACFs during the post-test phase of this study were above target. This
was the reason the TTR was recalculated without these first INRs to avoid potentially
skewing of the results, consistent with a practice suggested by some commentators in the
literature (Ansell et al. 2008; Witt 2011). All three new residents with high initial INRs after
admission in the current study were continuing with the dose of warfarin they had
reportedly been stabilised on prior to admission. This finding of an apparent discrepancy in
medication regimens between the reported and actual is consistent with other research
findings (Field et al. 2001; Tjia et al. 2009), as outlined below.
The first of these was a study conducted in 18 US nursing homes to investigate the
characteristics of the residents who experienced an adverse drug event (ADE), and found
that those who were newly admitted were more than twice as likely to experience an ADE
compared to those who were not (odds ratio [OR], 2.8; 95% CI, 1.5-5.2) (Field et al. 2001). In
a similar vein, the second study analysed medication discrepancies for patients newly
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admitted to two community-based “skilled nursing facilities” within long-term care facilities
in Central Massachusetts (Tjia et al. 2009). The results of this study by Tija et al. (2009)
showed that for over 20% of the medications prescribed on admission that were reviewed,
reconciliation with the resident’s confirmed regimen (from a variety of sources) was not
possible. Anticoagulants were responsible for nearly 7% of the discrepancies. As Tija et al.
(2009) demonstrated and has been found in the Australian setting (Pierce & Fraser 2009),
there is more than one possible source of medication information prior to admission to
residential aged care including that from the resident, the hospital discharge summary, fax
from community pharmacy or GP, or a phone message from hospital. It is prudent
therefore, that all these are considered to verify a new resident’s medication regimen.
Based on the findings of the present study and the supporting literature, it could be
recommended that the resident’s actual medication regimen prior to admission be
confirmed with as many sources as possible, and if this is not practical, then all medications
but especially warfarin be prescribed cautiously and with early monitoring implemented.

5.2.1.2 Warfarin dose adjustment
The current study findings suggest an improvement in the appropriateness of the response
to INRs outside the target range during the post-test phase, an indicator of quality use of
warfarin. For three residents with aberrant INRs in the pre-test phase who were not
managed appropriately according to consensus guidelines (Baker et al. 2004), the responses
by their GPs to subsequent aberrant INRs were appropriate; that is, the warfarin was
withheld initially and the dose reduced. It could be that the prompt of receiving the chart
with the INR documented above target was the catalyst for more timely and appropriate
action. As outlined in the literature review, the relevant quality indicator for hospital
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patients receiving warfarin is the proportion of INR results above 4.0 which incur an
appropriate review and action (NSW Therapeutic Advisory Group 2007). Due to the small
numbers of residents with an INR above 4.0 throughout the current study, it is impossible to
make any comparisons of pre- and post- intervention, based on this indicator.

5.2.1.3 Documentation of indication for warfarin
The current study found that there was an improvement in the documentation of the
indication for warfarin by the prescriber from the pre-test phase to the post-test phase, with
the provision of a specific prompt on the chart, with documentation for 75% of the residents
achieved in the post-test phase. This compares favorably with a study of the Australian
NIMC previously referred to, with documentation of an indication for warfarin found to be
26% in an audit of metropolitan Victorian hospitals (Leach 2007).
However for some residents in the present study, a likely warfarin indication was not
definitive based on their medical records, despite an indication noted on the chart. For
instance, a TIA in itself is not an indication for warfarin unless it is on the background of AF,
and yet for three residents this was the only likely indication for warfarin included in their
medical histories. Similarly, the presence of a pacemaker in situ is not a valid warfarin
indication, yet for one resident this was the only cardiac condition recorded and reinforced
the nurses’ beliefs as to its validity as an indication, as reflected on in the warfarin education
sessions.
The currency of the residents’ documented conditions and therefore relevant warfarin
indications according to their medical records also could not be assured, in the instances
when VTE was recorded. Of the five residents with either a PE or DVT noted, on one
occasion only was information documented as to the recency of the event. This is an
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important factor considering that compared to other indications for warfarin, VTE is the one
for which a treatment “course” or time-limit is often applied. The recommended duration of
treatment after an episode of VTE secondary to a transient (reversible) risk factor is three
months to six months (The National Working Party on the Management and Prevention of
Venous Thromboembolism 2004; Kearon et al. 2008; Kearon 2010). After an idiopathic
episode the optimum duration is uncertain especially in this older and less mobile
population, as both the risks of reoccurrence (off warfarin) and haemorrhage (on warfarin)
increases with age and time (The National Working Party on the Management and
Prevention of Venous Thromboembolism 2004; Kearon et al. 2008; Kearon 2010) and the
most prudent advice is to assess the risk: benefit ratio of continuing warfarin periodically
(Kearon et al. 2008). However, the application of this advice relies on the prescriber having
knowledge of particulars as to any antecedent events as well as the severity and
recurrences of VTE: details not reliably provided if the findings of the current study
regarding residents’ records are generalisable. So the information is not uniformly available
to enable such informed decisions.
In addition to the question of the rationality of either DVT or PE as indications for continuing
warfarin therapy, the findings of the current study also question the accuracy of the
documentation in residents’ medical histories, as there were in some cases differing or
more than one possible warfarin indication recorded. In the post-test phase, there were
instances when the indication according to the chart was “AF” without confirmatory
documentation in the notes, possibly reflecting the inconsistency in the residents’ medical
records and the methods by which conditions and comorbidities are recorded. This indicates
wider issues about accurate documentation of important medical information in aged care
settings, and concurs with the findings of the qualitative component of an investigation into
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medication errors in 55 American nursing homes, where a major emergent theme as a
contributor to error rates was the poor quality of the residents’ histories (Barber et al.
2009).
The absence of a convincing warfarin indication as a finding in the present study could also
be indicative of ineffective thorough medication review mechanisms: a more worrying
scenario considering that for three residents in the study (13% of participants), no indication
was ever documented or could be assumed. In research on dental procedures in
warfarinised patients, up to one third did not have a valid indication recorded (or had INRs
out of range prior to the procedure) (Goss & Carter 2002), and in a similar series of patients,
over 8% did not have any recorded indication for warfarin (Carter & Goss 2003). Both the
indication and therapeutic goal (target INR) are considered essential baseline parameters to
document for Australian hospital inpatients prescribed warfarin (self-assessment item 1.25)
in the tool for assessing hospital safety and quality indicators of warfarin (Clinical Excellence
Commission 2007); with good reason if this is completed with full knowledge. If there is
indeed no valid indication for warfarin, the resident is exposed to the risks of a potentially
toxic medication with unknown therapeutic benefit. One definition of polypharmacy
proposed - the prescribing and administration of more medications than are clinically
indicated (Hughes & Lapane 2011) - could be applied to the regimens of the residents
without a supporting indication for warfarin.

5.2.1.4 Documentation of target INR
Documentation of a target INR was improved in the post-test phase of the current study,
due to the specific prompt on the chart to record this. This finding is relevant as knowledge
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of the individual’s target INR was expressed as being necessary by the GPs and RNs in
interviews in the prior study (Jordan & Mullan 2008) as a prompt for action if an aberrant
INR was measured. Documentation of a target INR when warfarin is prescribed is a desirable
quality indicator for Australian hospital inpatients (Clinical Excellence Commission 2007) and
provision for such documentation is included also on the standardised Australian NIMC.
Again, compared with the best result of 49% documentation achieved in an audit of
concordance with this on the NIMC in Victorian hospitals (Leach 2007), the 75% achieved in
the post-test phase of the current study is a positive finding.

5.2.2 Safety implication: clinical outcomes

5.2.2.1 Warfarin-related adverse events
Over half of the residents who participated in the current study experienced a warfarinrelated adverse event, and for 70% of these an actual haemorrhagic event occurred. For
most of the times that an INR of over 4.0 was recorded, a concomitant haemorrhage was
noted in the medical records of the resident. This justifies, for this small series of patients at
least, the impetus to keep the INR within the target range. There was no difference in the
occurrence of actual haemorrhagic events noted between the phases of data collection. Any
such detectable difference would have been beyond the scope of this study due to its short
duration, the small number of participants with multiple risk factors present outside the
control of the strategy, and the cumulative nature of some haemorrhagic events. For
instance, a possible warfarin-related adverse event that occurred in one study resident was
bilateral chronic subdural haematomas, a documented adverse event more likely to occur in
older populations receiving warfarin (Rust, Kiemer & Erasmus 2004). The onset of this is
insidious and can take weeks to months to manifest (Ropper & Samuels 2009).
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The only specific study on the safety of warfarin in nursing homes from the literature
quantified the rate of actual adverse warfarin-related events as 18.8 per 100 residentmonths on warfarin (Gurwitz et al. 2007) based on data from 490 residents in 25 nursing
homes. It is therefore not possible to compare the results of Gurwitz et al. (2007) or the
calculated incidence of major haemorrhage in older populations of 3.2 and 13.1 per 100
patient-years by other researchers in different settings (van Walraven et al. 2002; Hylek et
al. 2007) with those of the present study. In this one, the incidence rate was not calculated
due to the small numbers, short duration of the study and the possible incomplete dataset
due to reliance on secondary sources. Also, as the severity of the haemorrhagic events was
not adjudicated, comparisons with literature reports based on severity are also not
plausible. In two studies on anticoagulant use in older, community-dwelling populations
however, the incidence of all haemorrhagic events in both studies was 12% (Palareti et al.
2000; Poli et al. 2007); considerably lower than the 39% in the present study.

The remainder of warfarin-related adverse events in the present study were instances when
the INR result was above the value of 3.5 (pre-defined as a potential adverse event); even
so, an actual haemorrhagic event occurred in over a third of these instances. Also, for 83%
of the occasions when the INR was measured above 4.0, a haemorrhagic event occurred.
This reflects relevant research such as by Oake et al (2008) which demonstrated that while
major haemorrhage can occur at an INR in the target range, the chance increases greatly
when above target. Oake et al (2008) calculated that for INRs results between 3.0 and 5.0,
the relative risk (RR) of a major haemorrhage occurring was more than doubled (RR = 2.7
[95% CI, 1.8- 3.9]) compared to results between the target of 2.0 and 3.0. While targeting an
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ideal range for the INR may reduce the risk of haemorrhage, the study also demonstrated
that not all actual haemorrhagic events occurred with aberrant INRs and for this older and
frail population there is a suggestion of an interplay of factors besides the INR such as age,
comorbidities and concurrent medications, as concluded in the relevant literature (Palareti
et al. 2000; Poli et al. 2007; Abdelhafiz & Wheeldon 2008; Abdelhafiz et al. 2009).

5.2.2.2 Concomitant and potentially inappropriate medications
The range in the number of regular medications (including warfarin) prescribed to
participant residents in the current study was 3-16, and the mean was 10. This mean
number of 10 regular medications is higher than the means of eight (Hosia-Randell,
Muurinen & Pitkala 2008) and nine (Bergman et al. 2007) found in international studies of
quality use of medications in nursing homes, and the mean of nine in two Australian studies
(Somers et al. 2010; Khalil 2011). Applying the literature definitions of polypharmacy based
on number of regular medications (le Couteur et al. 2004; Nguyen et al. 2006; Shi, Mörike &
Klotz 2008), between 68% and 91% of the study participants were receiving polypharmacy.
This is consistent with literature estimates of 65% in a Swedish study of nursing home
residents (Bergman et al. 2007) and 91% in the Western Australian study (Somers et al.
2010).

The finding in the present study of a mean of 10 medications provides an indicator for
possible adverse outcomes. Evidence for this is derived from research which has determined
the risk to nursing home residents of experiencing an adverse drug reaction when the
number of regular medications was five or more increased statistically between two and
four times, compared to fewer regular medications (McLean & le Couteur 2004; Nguyen et
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al. 2006). It was not possible in the present study to be able to make such comparative
calculations as only data relevant for warfarin were collected. However, as more than twothirds of the study residents received nine or more regular medications per day it is a
potential call for extra diligence in prescribing and monitoring, as ‘about one half of adverse
drug reactions in older people is preventable by better prescribing’ (le Couteur et al. 2004 p.
777).
For the purpose of this study, potentially inappropriate medications were defined as those
with a known likelihood of interacting with warfarin and administered concurrently, and
included all medications: those prescribed by the GP, after-hours doctors or given by RNs as
“nurse-initiated”. Such medications are considered “potentially” inappropriate as an
adverse reaction may not occur in all instances, especially if there is appropriate monitoring
and dosage adjustment of warfarin as necessary. Potentially inappropriate medications
were used for 91% of the residents at any time during the study period and in over a third of
instances of use, there was a clinically significant event for which the cause was possibly or
probably the drug-drug interaction. Examples of such events include the hospitalisation of a
resident with complications of a gastrointestinal haemorrhage when amiodarone and
aspirin were used with warfarin, without concomitant warfarin dosage adjustment; and for
another resident, widely fluctuating INRs when administered warfarin concurrently with
PEG feeds. Research into the quality use of warfarin in five Canadian nursing homes found
that 71% of their residents on warfarin were prescribed one or more possible interacting
medications, (Verhovsek et al. 2008) which is lower that the 91% of the current study.
Although comparisons across the two studies are not possible, any correlation with actual
clinical outcomes in the Canadian study was not investigated. However the Canadian
researchers did record if an INR was performed within 7 days of commencement of an
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interacting medication, an appropriate course of action by their definition. There was little
evidence in the present study of this occurring and in one case of a drug-drug interaction
with an increased dose of thyroxine, the result of the subsequent INR (continuing to be
performed monthly) was predictable and considerably raised.
Reassuringly, there was a suggestion of an increased awareness by RNs after attendance at
the warfarin education sessions provided in phase 2 of the present study, of the potential
for medications to interact. Communication with the respective GPs brought about a change
in either the way a medication was prescribed (for instance prn paracetamol altered to
regular) or more frequent INR testing in the instance of commencement of antibiotics.
Additionally, there was a change in practice of warfarin administration via the PEG feeding
tube. Even though the numbers are small, these examples suggest an improvement in
knowledge and emphasise the benefits of the education sessions, although follow-up data
were not collected as part of this study. Further, it is acknowledged that embedding a
change in knowledge was beyond the scope of the study. The information included in the
education sessions was not new and yet for some RNs as they admitted, it was. This
highlights a deficiency in the provision of initial and ongoing RN education, as the warfarin
information is available in standard nursing pharmacology texts (Bullock, Manias & Galbraith
2006; Tiziani 2008).
For the prescribers, the chart provided a prompt as to the role of concurrently administered
medications that the resident may have commenced or ceased since the previous review.
Electronic tools have been trialled internationally based on accepted “triggers” such as a
raised INR to detect an adverse event (Handler et al. 2008), but the response by the
physicians to such alerts generated have been disappointing (Rochon et al. 2005). GPs could
be alerted to the possibility of an inappropriate medication if all prescribing was electronic,
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although such systems again have had minimal success (Judge et al. 2006) and rely upon on
a current and accurate electronic medication record at the point-of-care. Although this is
ideal, an accurate electronic record is not always the situation in Australian RACFs when
multiple prescribers contribute to the medication regimen, many of whom are prescribing
off-site. Electronic prescribing on-site and ideally available for all prescribers could enhance
the potential for decision-support as well as generate alerts to interactions; however
despite enthusiasm of GPs and RACF managers, the findings from a single published trial on
electronic prescribing in residential aged care facilities in the Illawarra alluded to
infrastructure and technological problems as hindrances to outcomes (Burns et al. 2007).
From the current study and those referred to, it is apparent that the concurrent
administration of a potentially inappropriate medication with warfarin continues to be a
real phenomenon.

5.2.3 Evaluation summary: Safety implications
Analysis of the surrogate outcome measures evaluated in the warfarin-management
strategy showed trends towards improvements, with statistically significant improvement in
the documentation of the target INR, a desirable outcome according to guidelines and
voiced by those who manage warfarin. There were trends towards safer use of interacting
medications and more appropriate warfarin dosage adjustments. Due to the multitude of
factors contributing to clinical events, it was not possible to attribute any changes to the
warfarin-management strategy.
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5.3 Improving quality use of warfarin in residential aged care: other
research strategies
The aim of the present study was to improve the quality use of warfarin in local Illawarra
RACFs by the introduction of a new management strategy. There is a paucity of information
published about other strategies which demonstrate successful outcomes at all levels of
warfarin management in residential aged care, in either Australian or international
literature. An unpublished Australian study into the utilisation of information technology to
enhance warfarin management in Tasmanian age care facilities had limited success due to
the reliance on information technology (Peterson et al. 2007). Point-of-care testing of the
INR (using capillary blood via a ‘finger-prick’ test performed by RNs on-site rather than an
external laboratory) was utilised in the Tasmanian study, thus eliminating one level in the
warfarin management process. This method was also used by one of the three RACFs in the
present study, although it had been in use prior to commencement of the study and had not
led to improvements in the quality use of warfarin. As well as this Tasmanian study, another
from Canada also trialled a possible IT solution (Papaioannou et al. 2010) and while both
addressed the issues of monitoring and warfarin dosage recommendations, the final
recording and review of the medicine order and the administration processes, all valuable
steps in a medicines management pathway (Stowasser, Allinson & O'Leary 2004) were
neglected.
The qualitative evaluation findings from the present study suggested that communication
between prescribers and nursing staff at the participant RACFs was enhanced, and that
pertinent information to enable clinical decision making was more accessible. A similar
strategy designed to provide physicians with warfarin-relevant information using a
communication tool was trialled in 26 US nursing homes with 435 residents receiving
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warfarin (Field et al. 2011). In their study, trained nurses utilised a specific template
containing warfarin-relevant data (known as the ‘Situation, Background, Assessment, and
Recommendation (SBAR) approach) and communicated these to the prescriber via the
telephone. The outcome was that there was a modest increase in the TTR for the nursing
homes with the intervention compared to those control homes providing usual care;
however a statistically significant improvement in other quality indicators including
warfarin-related adverse events was not achieved. This large and well-supported study
reinforces the findings of those referred to above (Peterson et al. 2007; Papaioannou et al.
2010) as well as the present Illawarra study that demonstrating significant differences in
surrogate and actual outcomes in the labile and frail population with multiple comorbidities
and medications is difficult to achieve.
In none of these published studies was a significant reduction in warfarin-related adverse
events demonstrated, even though a large proportion of these could potentially be
prevented. Gurwitz et al (2007) deemed that 29% such events were predictable, and most
of these were due to errors in monitoring or prescribing. In the present study, there was no
direct input from the researcher into the management of warfarin as data were collected
retrospectively. Yet even in this small study, in over a third of instances when a medication
known to interact was given with warfarin there was an actual clinical event recorded in the
residents’ medical notes. As claimed in an editorial lamenting the high number of adverse
drug reactions in Australian general practice, ‘…it is clear that counting is not enough — it is
time for action, but what can be done?’ with an appeal for a systems approach involving
multiple strategies (Roughead & Lexchin 2006 p. 315). The present study findings were that
the new strategy enhanced some proponents of medication safety, and yet it ideally
requires augmentation with additional approaches.
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One such possible approach is to enhance the role of the clinical pharmacist in residential
aged care. In the present study, the two disciplines primarily involved in daily medication
management in the RACFS were nursing and medicine while the role of the pharmacists was
purely dispensing. The input of clinical pharmacists in residential aged care has resulted in a
range of findings which in some cases have included improved clinical outcomes (Hughes &
Lapane 2011). Medication management reviews by contracted accredited pharmacists are
one potential strategy that could improve the safety of medication such as warfarin
(Pharmaceutical Society of Australia 2006). But, as all three participating RACFs in the
current study had contracted medication management reviews processes in place, the
relevant findings suggests that the existing model was not effective in preventing adverse
outcomes. A model whereby advanced clinical pharmacist services are delivered on-site and
with the pharmacist as an active participant in the aged-care team is presently being piloted
in New Zealand residential aged care (Hikaka 2011). Early results are that the service is wellreceived with the majority of recommendations being acted upon. Although warfarin was
not specifically targeted in the New Zealand pilot program, this would be feasible given that
clinical pharmacists in Australian hospitals have traditionally undertaken a role in advising
on warfarin dosing, monitoring, and detecting drug interactions using a pre-emptive and
collaborative approach (Khoo & Bajorek 2006) which could be emulated in residential aged
care if a supported mechanism was in place. Further Australian research to investigate the
impact of pharmacy services on the use of inappropriate prescribing and adverse events in
the residential aged care setting has been advocated (Wilson et al. 2010).
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5.4

Improving quality use of warfarin in residential aged care: future
directions and recommendations

From the findings of the present study and those of the relevant literature, it is clear that a
range of approaches to achieve optimal quality use of warfarin in residential aged care is
necessary. Two further approaches are possible. The first of these is to consider
pharmacological alternatives to warfarin, given the difficulties in managing warfarin. The
most common alternatives to warfarin for AF are antiplatelet agents, alone or in
combination, yet these are not as effective as warfarin (Connolly et al. 2006; Aguilar, Hart &
Pearce 2007; Cairns et al. 2011) and have an inherent risk of haemorrhage as well (Shehab
et al. 2010).
Newer oral anticoagulants have become available with evidence for all the indications as for
warfarin (Ruff & Braunwald 2010; Galanis et al. 2011; Wann et al. 2011). At the time of
writing, the only agent approved and commercially available in Australia is dabigatran,
which has a recommendation for subsidisation for AF (Australian Government 2011c). For a
prescriber to consider dabigatran, the presence of AF and concurrent risk factors require
confirmation, which would limit the use in RACFs given the findings of the present study
that these are not reliably recorded. A thorough medication review process would be
necessary which in itself would be a desirable outcome. Further limitations to the
widespread adoption of dabigatran is that, with sub-group analysis of a key trial (Eikelboom
et al. 2011) and a broadening of its use outside the populations of the initial clinical trials,
alerts to its adverse effects in the older person have appeared (Legrand et al. 2011) most
recently from the Therapeutic Goods Administration of Australia (Australian Government
2011b). Advanced age was a likely contributory factor in the 47 serious bleeding events and
14 deaths that have occurred in Australia since 2009 up to the present time (Garrett 2011).
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So, despite the initial guarded optimism (Sahadevan & Cakulev 2010), it may be some time
yet before these agents become a real alternative to the older person treated with warfarin
in Australian RACFs. Also, the dabigatran capsule formulation cannot be stored outside its
original container nor opened, crushed or sprinkled on food due to changes in absorption
(NPS 2011; Australian Government 2011a), thus restricting its administration in RACFs with
their reliance on blister packaging of medications. In this context, the importance of the
warfarin-management strategy of the present study assumes even greater relevance for an
indeterminate future time, if there is to be a continued need for anticoagulation of residents
in aged care facilities as the age and comorbidities, hence the risk of AF, continues to rise.

A second approach to enhance the quality use of warfarin is for consideration to be given to
the validity of any form of anticoagulation in this frail, older population for whom there is
limited evidence of benefit but many indications of harm (Gurwitz et al. 2000; Hansen RA et
al. 2006; Gurwitz et al. 2007) and for whom it is apparently so difficult to optimise safety.
Although there is literature to support withdrawing of medications for older people, or
“deprescribing” (Woodward 2003; Le Couteur, Ford & McLachlan 2010; Hardy & Hilmer
2011), applying this to warfarin in a formalised manner has not been reviewed; indeed
warfarinised older people were excluded from participating in one pilot randomised
Western Australian trial of deprescribing in predominantly residents of aged care facilities
(Beer et al. 2011). Withdrawing warfarin has been discussed in the context of palliative care
for a patient with a malignancy (Spiess 2009) and there is also a recognition that those in
aged care may benefit from a palliative care approach. Guidelines exist to support a
palliative approach in RACFs (National Health and Medical Research Council 2006) and a
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project is currently taking place to implement training for this of staff and physicians of
Illawarra RACFs (Humpel 2010).
Whether warfarin constitutes a medication that should be routinely reviewed with a view to
withdrawal is one issue, but a relevant recommendation when considering “deprescribing”
is to ensure that there is an accurate medication regimen with knowledge of the indication
and duration of use for each agent (Woodward 2003). This is particularly pertinent given the
results of the present study when, for three residents, there was no valid possible indication
for warfarin recorded. For another resident with a documentation of AF and eight other
comorbidities (including dementia and “developmental delay” [sic]), the only other regular
medications besides warfarin were a laxative and an antipsychotic. For half the residents, an
antidepressant was included in their medication regimens and yet there was no associated
condition concurrently documented. “Deprescribing” in this case advocates a discussion
with the patient or carer(s) as to the risks and benefits (Woodward 2003) and the
uncertainties of the medication use for the patient (Le Couteur, Ford & McLachlan 2010). On
the results of the study, there is evidence that for many cases these conversations are not
occurring. Also, even with the availability of more comprehensive medical records of
residents’ histories, it has been estimated from a recent review of the literature that 44% of
nursing home residents (95% CI, 28% – 60%) are incapable of participating in the making of
such medical decisions (Sessums, Zembrzsuska & Jackson 2011).

5.4.1 Recommendations: summary
There were some positive outcomes attributable to this research that could be used to
enhance the quality use of warfarin in other residential aged care facilities outside those
which participated in this small study. GPs who have patients as older, high-level care
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residents in other local RACFs would benefit from a consistent approach if the management
strategy was more widely adopted. In addition, the Australian Commission on Safety and
Quality in Healthcare has, in its present remit, the standardisation of medication charts in
Australian RACFs (M Duguid Pharmaceutical Advisor, 2011, pers. comm., 7th November) and
has interest in the outcomes of the research presented in this thesis. Evaluation of the
strategy showed it was acceptable, usable and had the potential to enhance the safety of
older people prescribed warfarin, and thus can be recommended to be more widely
adopted.

5.5 Strengths and limitations of study
The study had several strengths. The strategy directly targeted several of the identified
barriers to quality use of warfarin (Jordan & Mullan 2008) and approached these in an
innovative manner, using the tools that were universally available to all participants. The
multidisciplinary input contributed to its acceptability. The strategy is the first of its kind to
be implemented in Australian RACFs which endeavoured to cover as many aspects along the
medication management pathway as possible. There was only one GP from the three RACFs
who did not participate and thus only one resident receiving warfarin who was not included
in the study sample. The demographics and practices of the GPs were such that the results
are generalisable outside of the study, as those involved were some of the oldest and
youngest within the Illawarra, and had minimal or wide ranging involvement in residential
aged care. Similarly, the acceptance by senior RNs who had been involved in all levels of
medication management as well as EENs with a more structured role, indicates
generalisability. The three RACFs who participated all were from different umbrella
organisations with very different models of care. Indeed soon after completion of the study,
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another RACF within the Illawarra adopted the strategy on the recommendation of a
participant GP.

The limitations of the study are that the numbers involved were small and that the
calculated sample size of 53 older residents prescribed warfarin was not achieved.
Contributing to this was that the management of one large RACF decided to implement the
prototype chart before the formal trial had begun, thus eliminating many more potential
participants. Also, as described in the methods, engaging the input from the large number of
GPs with patients in another potential RACF proved too difficult in the time-frame of the
study. Further limitations are that there was a reliance on secondary sources of information,
to record much of the data collected. Due to the small numbers involved, descriptive
statistics only were used so the significance or otherwise of the trend towards improved
surrogate outcomes could not be assured. Also, the study intentionally did not evaluate
efficacy of warfarin.

As acknowledged, a definitive role of potentially interacting medications could not be
assured in the haemorrhagic events that occurred and could only be assumed based on the
evidence-base of drug interactions. Reliance on facsimile transmission is not ideal in a time
of IT innovation; however it is the reality in residential aged care at the moment. As the
industry slowly moves to adopting more IT solutions, the chart could potentially be
incorporated. The method of evaluation may have been subjective and influenced by
opinion and personal preferences, although the participants were vocal throughout the
study about aspects that required attention so there is little reason they would not be
critical in the final assessment.
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5.6 Conclusions
This thesis has described the impetus for the development and implementation of a new
warfarin-management strategy and its evaluation in three RACFs. The strategy has been
evaluated as being accepted and easy to use as well as providing decision-support to
improve prescribing and potentially reduce warfarin-related adverse events and errors. In
addition, the thesis has described the changing environment of residential aged care as well
as the pharmacological options for anticoagulation, and provided a case for wider adoption
of the studied strategy as well as supplementary approaches to enhance the quality use of
medicines generally and warfarin in particular.
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APPENDIX 1 SEARCH STRATEGY

Search strategy 1
1

exp "Aged, 80 and over"/ or exp Aged/ or geriatric*.mp. or exp Geriatrics/ or
aging.mp. or exp Aging/

2.

warfarin.mp. or Warfarin/

3.

adverse drug reaction.mp. or exp Drug Toxicity/ or exp Hemorrhage/ or
h*emorrhage.mp

4.

exp Risk Factors

5.

nursing homes.mp. or exp Nursing Homes/ or homes for the aged.mp. or exp Homes
for the Aged/ or exp Long-Term Care/ or exp Housing for the Elderly/ or exp Homes
for the Aged/ or exp Health Services for the Aged/ or residential facilities.mp. or exp
Residential Facilities/

6.

exp Medication Errors/ or medication administration.mp. or medication chart.mp.

or medication management.mp or exp Medication Systems/
7

1 and 2

8.

2 and 3 and 4

9.

2 and 5

10.

5 and 6

11.

7 or 8 or 9 or 10 or 11

SEARCH STRATEGY 2
1.

Warfarin/

2.

exp Heart Valve Prosthesis/ or exp Heart Valve Prosthesis Implantation/

3.

exp Venous Thrombosis/pc, th [Prevention & Control, Therapy]

4.

exp Pulmonary Embolism/dt, ep, pc, th [Drug Therapy, Epidemiology, Prevention &
Control, Therapy]

5.

exp "Aged, 80 and over"/ or exp Aged/

6

exp Geriatrics/th [Therapy]

7.

5 or 6

8.

2 or 3 or 4
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9.

1 and 7 and 8

10.

limit 9 to (english language and humans and yr="2001 -Current")
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APPENDIX 2 PILOT WARFARIN-SPECIFIC MEDICATION CHART
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APPENDIX 3 HUMAN RESEARCH ETHICS COMMITTEE APPROVAL
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APPENDIX 4 WARFARIN EDUCATION SESSION - OUTLINE

Warfarin education

The purpose of the warfarin education sessions was
•

to provide a background to the therapeutic use of warfarin;

•

to remind those responsible for warfarin management and care of the older
persons receiving warfarin of the specific concerns around warfarin use, and

•

to introduce the proposed warfarin-management strategy with particular
emphasis on the workings of the associated warfarin-specific medication chart.

Learning objectives

After attending the warfarin education session, participants should be able to
1.

outline the mechanism by which warfarin exerts its effect and the role of
vitamin K.

2.

understand how changes to a resident’s food intake and concurrent health
conditions can influence the response to warfarin

3.

understand the requirements of monitoring the therapeutic and adverse
effects of warfarin, and apply this understanding to observe and respond to a
resident’s warfarin-related outcome.

4.

explain the rationale behind the warfarin-management strategy to be trialled
and apply an understanding of warfarin management to interpreting the
medication chart.
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To introduce the warfarin education sessions and encourage the participants to consider the
factors that could impact on warfarin and to reflect on current practices, all attending were
invited to complete an anonymous warfarin questionnaire. Not all participants completed
the questionnaires and their decisions not to respected; as per Human Research Ethics
recommendations. Responses from the participants were collated and summarised in
Chapter 4 Findings.

By including this at the beginning of the session, the aim was to focus the participants’
attention on the nuances of warfarin management, and to review prior knowledge as well
as to engender some early discussion. Accordingly, a reflective learning opportunity was
introduced for those participants who had an active role in the management of warfarin and
communication with prescribing GPs.

Warfarin- interactive workshop

The focus of the following component of the education session was on specific messages
about warfarin, its mechanism of action and its indications. This was delivered using a
question and answer format (Appendix 5, questions 1 and 2) to encourage active
involvement from the participants. As it was recognised that some of the participants were
from non-clinical or unrelated nursing backgrounds, didactic delivery also was incorporated
as necessary to emphasise the mechanism of action and the role of vitamin K, and to
confirm and summarise the participants’ responses via a PowerPoint® presentation
(Appendix 6). As the factors that impact on warfarin can alter daily in the older person in
residential care, it was important that these be stressed.
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Various myths as to the indications of warfarin are held, and evidence exists that not all
those who receive warfarin have a valid or current indication (Goss & Carter 2002); hence
the inclusion of a prompt (Appendix 5 question 3) to elaborate on this theme.

Supporting references and theory for this component

Standard pharmacology texts and literature (Chaffman 2001; Glasheen 2005; AMH 2011)
and alerts recognising warfarin as a drug at high risk of causing adverse events (NSW Health
2007; Makeham, Saltman & Kidd 2008) were used as to structure this component.

Monitoring warfarin therapy

The next component discussed how the therapeutic effects are monitored, utilising specific
prompts in the questionnaire (Appendix 5 questions 4 and 5). The trigger questions asked
were about potential responses to hypothetical INR results; however discussions included
the role of monitoring for clinical toxicity as well.

Warfarin-related adverse events were covered in this component. Courses of action to take
if a resident experienced an adverse event were offered by the participants. The
recommended management of aberrant INR values, with or without clinical haemorrhage
was presented; emphasising that all residents in RACFs, by inclusion, are at high-risk of
bleeding. The consensus guidelines for the management of warfarin-related adverse events
(Baker et al. 2004) were included in the accompanying manual provided to the RACFs and
these were pointed out and discussed in more detail.
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Warfarin and older people in Aged Care

The next component of the warfarin education session focused on the mechanisms by
which older people residing in Aged Care facilities were at high risk of experiencing a
warfarin-related adverse event: due to their frailty, risks of falls and concurrent conditions
and medications. There is a wealth of supporting literature for this component (Chaffman
2001; Bob 2003; Bereznicki et al. 2006; Fang et al. 2007; Gurwitz et al. 2007).

Conclusion of warfarin education components

Using a problem-based approach at the end of this component encouraged the participants
to reflect on, and in some cases question their current practices. Staff were encouraged to
recall from their collective wealth of aged care experience, specific relevant cases. For
instance, cases of fluctuating INR values, residents who had experienced warfarin-related
haemorrhages, and discussing those residents for whom warfarin was considered not an
appropriate medication were some of the experiences examined. As there was a mixture of
nursing backgrounds (acute care, management, and unrelated clinical areas for instance,
drug and alcohol and disabilities) these discussions were important to consolidate the early
components of the sessions.

Participation in trial of the Warfarin Management Strategy

The final component of the education session was used to
•

outline the trial in which the facility was to participate;

•

introduce the warfarin-specific medication chart (Appendix 2)

•

highlight relevant procedures for which the nurses responsible for warfarin
management had a role,
165

•

address any concerns as raised; and

•

display the laminated “how-to” poster (Appendix 7) and resource manual
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APPENDIX 5 WARFARIN INTERACTIVE WORKSHOP QUESTIONS

Warfarin
1. What is warfarin?

2. How does warfarin work?

3. Why would a resident of your facility be prescribed warfarin?

4. What would be an INR result that you would expect a resident to have?

5. How would you react to an INR result of 3.5?

6. How would you react to an INR result of 5?

7. What are some considerations that are important in managing an older
person on warfarin?
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APPENDIX 6 WARFARIN EDUCATION SESSION: POWERPOINT® SLIDES
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APPENDIX 7 “HOW-TO” WALL POSTER
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APPENDIX 8 GP SEMI-STRUCTURED INTERVIEW - QUESTIONS

“The introduction and evaluation of a warfarin management
strategy into Residential Aged Care Facilities”
Code____

Please do not write your name

1. I How many patients do you have who are current residents of Residential Aged
Care Facilities?

……………………………..

2. In how many of these Residential Aged Care Facilities do you have patients
currently prescribed warfarin?

……………………………..

3. In how many of Residential Aged Care Facilities did you have the opportunity
to trial the new warfarin management strategy?
………………………………

4. For how many of your patients who were residents of RACFs receiving warfarin
did you trial the warfarin –management strategy (in total across all facilities)?
………………………………
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5. Prior to the implementation of the new warfarin management strategy, what
was the MAIN method that you used when making warfarin dosage adjustments
for your patients in a Residential Aged Care Facility?

Personally, over the phone
Over the phone via the receptionist
Over the phone via the practice nurse
Via fax
Personally, when visiting the facility
Other

(Please

specify)

…………………………………………………………………

6. With respect to the prescribing of warfarin, in your opinion did the strategy
make prescribing warfarin-

easier.
more difficult
neither easier nor more difficult.

7. During the trial, did you ever receive information in the section of the warfarin
chart designed to alert you to changes in the resident receiving warfarin that
may have an effect of warfarin?

No, never
I can’t remember
Yes, once
Yes, more than once
Yes, many times
(please provide more details if you wish as to the circumstances).
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
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8. With respect to communication with the Aged Care Facility, compared to
before the strategy was introduced, in your opinion did the warfarin chart?

Enhance communication.
Hinder communication.
There was no change to communication.

9. Considering your time, compared to before the strategy was introduced, by the
end of the study did the warfarin- medication chart?

Take more time to use than previous methods
Take more time to use, but was more comprehensive
Saved time

10. Would you say that the warfarin chart was?
Easy to use
Hard to use
Hard at first but I got used to it

11. What would you say was the BEST feature of the warfarin-specific medication
chart?
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………..
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12. What would you say was the WORST feature of the warfarin-specific medication
chart?

………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………..

13. Would you like to see the warfarin management strategy adopted for warfarin
prescribing in Residential Aged Care Facilities?

Yes
No

(Please explain)
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………….

14. Please provide any specific feedback about the warfarin medication chart
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………….

Thank you for your time- it is much appreciated
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APPENDIX 9 RN SEMI-STRUCTURED INTERVIEW – QUESTIONS

“The introduction and evaluation of a warfarin management
strategy into Residential Aged Care Facilities”
Code____

Please do not write your name or that of your facility.
1. What level of care is provided in the Residential Aged Care Facility in which you
are employed?

High

(go to question 4)

Low

(go to question 4)

Both (go to question 2)

2. Considering your main role in medication management, for what level of care
are you responsible?

High
Low

3. Do you have any role in medication management in any other area of this
facility?
(If yes, please provide details)
……………………………………………………………………….............................................
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………….
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4. Are you familiar with the warfarin management strategy that has been
introduced in this facility over the last few months?

Yes

(please continue)

No

(No further questions. Thank you for your time)

5. If yes, have you been involved in the management of warfarin and therefore
had an opportunity to use the new warfarin medication charts being evaluated?

Yes, all of the time
Yes, sometimes
Yes, rarely
No

(No further questions. Thank you for your time)

6. If yes, did you receive training about how the chart was intended to be used?
Yes
No

7. Please estimate the number of residents prescribed warfarin for whom you
have used the warfarin-medication chart.

……………………………………………………..
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8. With respect to communication with the GP about the resident’s warfarin
therapy, compared to the usual warfarin management strategy prior to the
introduction of the new chart, in your opinion did the new warfarin chart

Enhance communication?
Hinder communication?
There was no change to communication.
Other (please discuss)
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………..

9. With respect to the administration of warfarin, compared to the usual
warfarin management strategy prior to the introduction of the new chart, in
your opinion did the new warfarin chart

make it easier to find the prescribed dose of warfarin
make it more difficult to find the prescribed dose of warfarin
make it neither easier nor harder to find the prescribed
warfarin dose

10. What would you say was the BEST (if any) feature of the warfarin medication
chart?
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………..
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11. What would you say was the WORST (if any) feature of the warfarin medication
chart?
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………..

12. During the trial of the warfarin chart, did you ever use the section designed to
alert the GP about changes in the resident that may have impacted on their
warfarin therapy?
No, never
I can’t remember
Yes, once
Yes, more than once
Yes, many times

(please provide more details if you wish as to the circumstances).
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………..

13. Considering nursing staff time, compared to the usual warfarin management
strategy prior to the introduction of the new chart, in your opinion did the new
warfarin chart by the end of the trial?

Take more time to use than previous methods
Take more time to use, but provided more information
Save time
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14. Prior to the trial of the new warfarin medication chart, how was the dose of
warfarin MOST COMMONLY adjusted by the GPs for residents in your facility?

Over the phone by the GP
Over the phone by the GP’s receptionist or practice
nurse
Via fax from the GP
Personally, by the GP when visiting
Other
(please specify)……………………………….………………………

15. In your opinion, was the new warfarin chart?
Easy to use
Hard to use
Hard at first but easy once you got used to it.
Other (please specify)

16. Would you like to see the new warfarin charts adopted for use in this facility?
Yes
No

(Please explain)
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………

17. Please provide any specific feedback about the new warfarin medication chart.
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………..

Thank you for your participation- it is very much appreciated
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APPENDIX 10 FINAL WARFARIN MEDICATION CHART AFTER MODIFICATIONS
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